Original Article

Calcium plus Vitamin D Supplementation and the Risk of Colorectal Cancer

Jean Wactawski-Wende, Ph.D., Jane Morley Kotchen, M.D., Garnet L. Anderson, Ph.D., Annlouise R. Assaf, Ph.D., Robert L. Brunner, Ph.D., Mary Jo O'Sullivan, M.D., Karen L. Margolis, M.D., Judith K. Ockene, Ph.D., Lawrence Phillips, M.D., Linda Pottern, Ph.D., Ross L. Prentice, Ph.D., John Robbins, M.D., Thomas E. Rohan, Ph.D., Gloria E. Sarto, M.D., Santosh Sharma, M.D., Marcia L. Stefanick, Ph.D., Linda Van Horn, Ph.D., Robert B. Wallace, M.D., Evelyn Whitlock, M.D., Tamsen Bassford, M.D., Shirley A.A. Beresford, Ph.D., Henry R. Black, M.D., Denise E. Bonds, M.D., Robert G. Brzyski, M.D., Bette Caan, Dr.P.H., Rowan T. Chlebowski, M.D., Barbara Cochrane, Ph.D., Cedric Garland, Dr.P.H., Margery Gass, M.D., Jennifer Hays, Ph.D., Gerardo Heiss, M.D., Susan L. Hendrix, D.O., Barbara V. Howard, Ph.D., Judith Hsia, M.D., F. Allan Hubbell, M.D., Rebecca D. Jackson, M.D., Karen C. Johnson, M.D., Howard Judd, M.D., Charles L. Kooperberg, Ph.D., Lewis H. Kuller, M.D., Andrea Z. LaCroix, Ph.D., Dorothy S. Lane, M.D., Robert D. Langer, M.D., Norman L. Lasser, M.D., Cora E. Lewis, M.D., Marian C. Limacher, M.D., and JoAnn E. Manson, M.D. for the Women's Health Initiative Investigators

N Engl J Med 2006; 354:684-696February 16, 2006DOI: 10.1056/NEJMoa055222

Abstract

Background

Higher intake of calcium and vitamin D has been associated with a reduced risk of colorectal cancer in epidemiologic studies and polyp recurrence in polyp-prevention trials. However, randomized-trial evidence that calcium with vitamin D supplementation is beneficial in the primary prevention of colorectal cancer is lacking.

Methods

We conducted a randomized, double-blind, placebo-controlled trial involving 36,282 postmenopausal women from 40 Women's Health Initiative centers: 18,176 women received 500 mg of elemental calcium as calcium carbonate with 200 IU of vitamin D3 twice daily (1000 mg of elemental calcium and 400 IU of vitamin D3) and 18,106 received a matching placebo for an average of 7.0 years. The incidence of pathologically confirmed colorectal cancer was the designated secondary outcome. Baseline levels of serum 25-hydroxyvitamin D were assessed in a nested case–control study.

Results

The incidence of invasive colorectal cancer did not differ significantly between women assigned to calcium plus vitamin D supplementation and those assigned to placebo (168 and 154 cases; hazard ratio, 1.08; 95 percent confidence interval, 0.86 to 1.34; P=0.51), and the tumor characteristics were similar in the two groups. The frequency of colorectal-cancer screening and abdominal symptoms was similar in the two groups. There were no significant treatment interactions with baseline characteristics.

Conclusions

Daily supplementation of calcium with vitamin D for seven years had no effect on the incidence of colorectal cancer among postmenopausal women. The long latency associated with the development of colorectal cancer, along with the seven-year duration of the trial, may have contributed to this null finding. Ongoing follow-up will assess the longer-term effect of this intervention. (ClinicalTrials.gov number, NCT00000611.)

Media in This Article

Figure 1Estimated Effects of Supplemental Calcium with Vitamin D on the Risk of Colorectal Cancer, According to Selected Baseline Characteristics.
Figure 2Rates of Adherence (Panel A) and Bowel Examination (Panel B) in the Two Groups during the Study.
Article

As the second leading cause of death from cancer in the United States,1 colorectal cancer is the focus of considerable preventive effort.2 Most observational studies have associated increased calcium and vitamin D intake with a decreased risk of colorectal cancer3-6 and recurrent polyps.7,8 Although the results are somewhat mixed, one pooled analysis of 10 cohort studies that assessed dietary consumption and total calcium intake (diet plus supplements) reported a reduction in the incidence of colorectal cancer of 10 to 15 percent,9 whereas an earlier pooled analysis found no effect.10 The suggestion that increased calcium intake helped prevent colorectal cancer led to randomized clinical trials that found that calcium supplementation lowered the incidence of recurrent colorectal polyps to some degree,11,12 with one report demonstrating that this protection was confined to subjects with higher endogenous vitamin D levels.13 As part of the Women's Health Initiative (WHI), we conducted a randomized clinical trial to determine whether calcium plus vitamin D supplementation would help prevent colorectal cancer and to examine the effect of supplementation on bone mineral density and the risk of fractures. We report the results related to colorectal cancer; the results related to fracture and bone mineral density are reported elsewhere in this issue of the Journal.14

Methods

Between 1993 and 1998, postmenopausal women 50 to 79 years of age were enrolled in the WHI randomized trials assessing the risks and benefits of hormone therapy and dietary modification.15-18 Exclusion criteria were related to competing risks, safety, adherence, and retention. One year later, these participants were invited to enroll in the calcium plus vitamin D trial, designed to determine whether calcium plus vitamin D supplementation would prevent hip fracture (the primary outcome) and colorectal cancer (a designated secondary outcome), as described by Jackson et al.14 Exclusion criteria for the calcium plus vitamin D supplementation trial included a predicted survival of less than three years, a history of renal calculi or hypercalcemia, current use of oral corticosteroids, and current daily use of at least 600 IU of supplemental vitamin D or calcitriol.19 Ninety-one percent joined the calcium with vitamin D portion of the study during their first annual visit, and 9 percent the following year. Fifty-four percent of the participants had been enrolled in the trials assessing hormone therapy, 69 percent had been enrolled in the trial assessing dietary modification, and 14 percent had participated in both trials. The protocol and consent forms were approved by the institutional review board at each participating institution. All women provided written informed consent.

Randomization, Blinding, and Intervention

A permuted-block algorithm was used for randomization, with participants stratified according to clinical center and age. Among the 36,282 participants, 18,176 were randomly assigned to receive one tablet of 500 mg of elemental calcium as calcium carbonate combined with 200 IU of vitamin D3 (GlaxoSmithKline) twice daily (total, 1000 mg of elemental calcium and 400 IU of vitamin D3) and 18,106 to receive an identical-appearing placebo tablet twice daily. Blinding of the study was achieved by bottle labeling.15 Participants were given chewable tablets until 1997, at which time tablets that could be swallowed were also offered. Initially, 61 percent of the women in both groups were given chewable tablets. By the end of the study, 70 percent chose the formulation that could be swallowed. Two years after randomization, a comparison of serum 25-hydroxyvitamin D levels in 227 women in the group given calcium with vitamin D and 221 women in the placebo group revealed that the levels were 28 percent higher in the supplement group.

Before enrollment, participants had blood drawn after a 12-hour fast. Samples were processed, frozen at −70°C, and stored according to standardized protocols. After a review of initial findings, a nested case–control study was proposed to determine whether the serum 25-hydroxyvitamin D level at baseline modified the outcome. As of April 8, 2005, 317 women with confirmed invasive colorectal cancer were matched according to age, center, race or ethnic group, and the date of blood sampling with 317 control women who were randomly selected from the group of participants who were free of colorectal cancer. Of these 317 pairs, 306 had adequate stored serum for analysis. Bruce Hollis, Ph.D. (Stillwater, Minn.), measured serum 25-hydroxyvitamin D levels using the DiaSorin Liaison 25(OH)D chemiluminescent radioimmunoassay system, which has an interassay coefficient of variation of 11.8 percent.

Follow-up Procedures and Ascertainment of Outcomes

Participants were telephoned four weeks after randomization to assess abdominal symptoms and reinforce the importance of adherence; they were contacted semiannually thereafter for self-reported updates on medical history. Any reported colorectal cancers were verified in a blinded fashion by local and central physician adjudicators and coded with the use of the Surveillance, Epidemiology, and End Results system20,21; 99.4 percent of reported cancers were centrally confirmed. Adherence was assessed by weighing returned pill bottles. Regardless of their level of adherence, participants were followed up until they died, were lost to follow-up, or requested no further contact or until the study ended.

The protocol did not include a requirement for colorectal-cancer screening; any such tests were ordered by each participant's personal physician. The frequency of rectal examination, fecal occult-blood testing, sigmoidoscopy or colonoscopy, and barium enema was ascertained during medical-history updates. The frequency of abdominal symptoms (bloating or gas, constipation, diarrhea, nausea, a change in appetite, heartburn, and stomach upset) was assessed by a self-administered questionnaire at the time of enrollment in the calcium with vitamin D study; in a random subsample at years 3, 6, and 9; and among all participants, at the completion of the study. Such symptoms were managed by temporary reduction in the number of pills taken. Study pills were discontinued if kidney stones, hypercalcemia, dialysis, or the use of calcitriol or of daily supplements of more than 1000 IU of vitamin D was reported.

Study Monitoring and Termination

An independent data and safety monitoring board reviewed the trial data semiannually.15 By design, early stopping considerations were based on comparisons between groups of the incidence of hip fracture, colorectal cancer, breast cancer, and death from other causes. Closeout visits occurred as planned between October 1, 2004, and March 31, 2005, with outcomes assessed before the treatment assignment was revealed.

WHI investigators and National Institutes of Health sponsors all contributed to the study design and execution. All authors helped write or revise the manuscript. Statistical analyses and data management were conducted at the WHI Clinical Coordinating Center, whose members vouch for the completeness and veracity of the data and analyses.

Statistical Analysis

Primary analyses used time-to-event methods, according to the intention-to-treat principle. The incidence of colorectal cancer was compared in the two groups with the use of hazard ratios (with 95 percent confidence intervals) and Wald statistic P values from Cox proportional-hazards models,22 stratified according to age, history of colorectal cancer, and treatment assignment in the Hormone Therapy and Dietary Modification trials. The use of a two-sided, weighted log-rank test was specified in the protocol, with weight increasing linearly from zero at randomization to a maximum of one at 10 years, to enhance the statistical power of the study according to the design assumptions. Both Bonferroni's adjusted and unadjusted tests of significance are given for the weighted log-rank test. The adjusted tests take into account the four end points indicated in the study monitoring plan. Kaplan–Meier estimates were used to describe event rates over time. Potential differential effects across subgroups of important risk factors for colorectal cancer were tested individually with the use of a likelihood ratio test for interaction between the risk factor and treatment assignment after including both as main effects. Thirty-seven subgroup comparisons were tested, with 19 reported (those not reported include the number of first-degree relatives with colorectal cancer; geographic location, tested with the use of two additional methods; any personal use of calcium supplements; the duration and recency of use of hormone therapy; the use of hormone therapy among participants in the dietary-modification trial; and 10 interactions evaluated in women with invasive colon, not rectal, cancer). Accordingly, the results of two tests would be expected to be significant at the 0.05 level by chance. Participants with missing values were excluded from analyses requiring that value.

In planning the study, we calculated that for the secondary end point of colorectal cancer, a trial involving 35,000 women who were followed for an average of eight years would have a statistical power of 83 percent to detect an absolute reduction in the incidence of colorectal cancer of 22 percent with calcium with vitamin D supplementation, as compared with placebo (given an α value of 0.05). The interaction between serum 25-hydroxyvitamin D levels at baseline and randomized assignment to calcium with vitamin D supplementation or placebo was assessed with the use of conditional logistic regression. Tests for trend and interaction used the logarithm of serum 25-hydroxyvitamin D levels. All reported P values are two-sided and, along with the confidence intervals, were not adjusted for multiplicity, unless noted.

Results

Between 1995 and 2000, 36,282 women underwent randomization. Age, self-reported race or ethnic group, level of education, body-mass index, presence or absence of a family history of colorectal cancer, presence or absence of a history of polyps, level of physical activity, caloric intake, saturated fat intake, multivitamin use, personal intake of elemental calcium, personal intake of vitamin D, level of ultraviolet exposure, cigarette-smoking status, history of hormone use, and randomized assignment in the Hormone Therapy and Dietary Modification trials were similar in the two groups (Figure 1Figure 1Estimated Effects of Supplemental Calcium with Vitamin D on the Risk of Colorectal Cancer, According to Selected Baseline Characteristics.).14 The mean (±SD) duration of follow-up was 7.0 ±1.4 years, with a maximum of 9.7 years. During year 1, 60 percent of the participants took at least 80 percent of their study medication, and this percentage remained stable through year 6, with small differences between groups (Figure 2AFigure 2Rates of Adherence (Panel A) and Bowel Examination (Panel B) in the Two Groups during the Study.). At least 70 percent took 50 percent or more of their study medication through year 6.

The frequency of bowel examination was similar in the two groups throughout follow-up (Figure 2B). In each group, 60 percent of participants underwent sigmoidoscopy, flexible sigmoidoscopy, or colonoscopy at least once during the study, whereas 15 percent had no bowel assessment of any kind.

Data on events were available for 97 percent of living participants within 18 months before the end of the study. At the time the study ended, 352 women assigned to calcium with vitamin D supplements and 332 women assigned to placebo had withdrawn; 144 and 152, respectively, had been lost to follow-up; and 744 and 807, respectively, had died. A total of 339 colorectal cancers were reported. Of these, nine were in situ and eight were primary cancers of other sites.

Analyses limited to the 322 invasive colorectal cancers revealed that calcium with vitamin D supplementation, as compared with placebo, had no effect on the risk of colorectal cancer (168 vs. 154 cases; hazard ratio, 1.08; nominal 95 percent confidence interval, 0.86 to 1.34; P=0.51) (Figure 3Figure 3Kaplan–Meier Estimates of the Cumulative Hazard for Invasive Colorectal Cancer with Supplemental Calcium plus Vitamin D, as Compared with Placebo.). The protocol-specified, weighted log-rank test yielded an unadjusted P value of 0.26 and a P value of 0.32 after adjustment for multiple outcomes. Sensitivity analyses censoring follow-up on participants six months after their rate of adherence to the study medication dropped below 50 percent did not change the findings (hazard ratio in the supplement group as compared with the placebo group, 1.08; 95 percent confidence interval, 0.83 to 1.39), nor did censoring follow-up six months after adherence dropped below 80 percent (hazard ratio, 0.98; 95 percent confidence interval, 0.73 to 1.32). Analyses excluding the 36 women in the supplement group and the 38 women in the placebo group with prior colorectal cancer yielded similar results (hazard ratio for the comparison of the supplement group with the placebo group, 1.09; 95 percent confidence interval, 0.87 to 1.36; P=0.44). No significant interactions were found with any baseline characteristic examined (Figure 1).

Personal use of any calcium supplementation was reported by 54 percent of the participants at baseline, rising to 69 percent at annual visit 9. The mean dose increased by less than 100 mg per day (from 325 mg per day at enrollment) during this interval and was similar across treatment groups. Modeling personal use of calcium supplements as a time-dependent covariate left the hazard ratio essentially unchanged (hazard ratio, 1.06; 95 percent confidence interval, 0.85 to 1.32). The interaction between personal use of calcium supplementation over time and treatment group was not significant (P=0.25).

The location, histologic characteristics, grade, stage, and size of colorectal cancers were similar in the two groups (Table 1Table 1Incidence of and Annualized Percentage of Women with Invasive Colorectal Cancer and Other Outcomes.). In the supplement group, as compared with the placebo group, hazard ratios for invasive colon cancer (hazard ratio, 1.00; 95 percent confidence interval, 0.78 to 1.28; P=0.99), invasive rectal cancer (hazard ratio, 1.46; 95 percent confidence interval, 0.92 to 2.32; P=0.11), proximal-colon cancer (hazard ratio, 0.95; 95 percent confidence interval, 0.69 to 1.30; P=0.74), and distal-colon cancer (hazard ratio, 1.08; 95 percent confidence interval, 0.69 to 1.69; P=0.73) did not differ from unity. The hazard ratio for death from colorectal cancer was 0.82 in the supplement group as compared with the placebo group (95 percent confidence interval, 0.52 to 1.29; P=0.39); however, too few events had occurred (34 vs. 41) to make the comparison meaningful.

Safety and Tolerability

As of March 31, 2005, 744 women in the supplement group had died, as compared with 807 women in the placebo group (hazard ratio, 0.91; 95 percent confidence interval, 0.83 to 1.01; P=0.07). Supplementation with calcium plus vitamin D was not associated with any significant risk or benefit with respect to any major disease outcomes, including cardiovascular diseases and cancer. The effects of calcium plus vitamin D supplementation, as compared with placebo, on the total risk of cancer (hazard ratio, 0.98; 95 percent confidence interval, 0.91 to 1.05; P=0.53) and the risk of death from cancer (hazard ratio, 0.89; 95 percent confidence interval, 0.77 to 1.03; P=0.12) were not significant.

The self-reported occurrence of polyps (all types combined) was similar in the supplement group and the placebo group (hazard ratio, 0.99; 95 percent confidence, 0.94 to 1.04; P=0.71). Kidney stones were reported by 449 women in the supplement group, as compared with 381 women in the placebo group (hazard ratio, 1.17; 95 percent confidence interval, 1.02 to 1.34; P=0.02).

Overall, the supplements were well tolerated. There was no significant difference between groups in the frequency of reported symptoms at any time. The frequency of any moderate or severe abdominal symptom in the four weeks preceding enrollment was 34 percent in both groups, increasing to 39 percent in the group assigned to calcium with vitamin D supplementation and to 37 percent in the placebo group at annual visit 3 (P=0.29).

Serum Vitamin D Levels

Findings from the nested case–control study revealed no significant interaction between serum 25-hydroxyvitamin D levels at baseline and treatment assignment (P=0.54). However, analyses adjusting only for case–control matching demonstrated a significant inverse trend with lower baseline levels of serum 25-hydroxyvitamin D associated with an increased risk of colorectal cancer (P for trend=0.02) (Table 2Table 2Odds Ratios for Invasive Colorectal Cancer According to the Quartile of Serum 25-Hydroxyvitamin D Level at Baseline and Treatment Groups in a Nested Case–Control Study.).

Discussion

In this randomized clinical trial, daily supplementation with 1000 mg of elemental calcium as calcium carbonate combined with 400 IU of vitamin D3 for an average of seven years had no detectable effect on the incidence of colorectal cancer among postmenopausal women. This absence of an effect was consistent across subgroups, including personal calcium and vitamin D intake and serum vitamin D levels at baseline. Thus, our findings fail to validate previous observational studies and polyp-prevention trials associating calcium and vitamin D intake with reduced risk.

Adherence was relatively good throughout the trial among the more than 36,000 women enrolled; thus, we had sufficient power to detect a 20 percent difference in risk. How should our findings be interpreted in the context of the body of published literature and a growing public perception that calcium and vitamin D supplementation can prevent colorectal cancer? Previous observational studies have often interpreted the protection afforded by calcium and vitamin D supplementation only in the context of comparisons of extreme quintiles of intake. Findings from observational studies should be reviewed cautiously, since they are more prone to confounding and bias than are randomized clinical trials,24 especially with respect to the assessment of preventive behaviors that may be difficult to detect, measure, and control for. The randomized trial design we used has greater potential to limit bias.

Previous trials demonstrating beneficial effects of calcium and vitamin D supplementation, such as polyp prevention, have led to the use of these agents in risk-reduction strategies. However, there has been no demonstration that secondary prevention of polyps with calcium and vitamin D supplementation translates into a reduction in colorectal cancer. We found no evidence that calcium with vitamin D supplementation prevented colorectal cancer. Although self-reported, the incidence of polyps was also similar in the supplement and placebo groups. As such, our results raise questions regarding the widely held concept that calcium and vitamin D supplementation will prevent colorectal cancer.

Our randomized clinical trial had the potential to limit biases inherent in observational studies and moved beyond trials of secondary prevention of colon polyps. However, issues regarding the design and study population may have limited our ability to demonstrate a protective effect of calcium with vitamin D supplementation on the risk of colorectal cancer, if one does exist. Participants were healthy postmenopausal women selected to be generally free of disability and clinically dominant chronic illness. By design, participants were not restricted from taking calcium or vitamin D supplements on their own. At enrollment, participants had mean total calcium (1151 mg) and vitamin D (367 IU) intakes that were twice the national average25 and nearly met current recommendations.26 Intakes rose during the trial, while national averages remained relatively stable.27 These high intakes may have limited our ability to affect the rates of colorectal cancer further. One prospective study found no additional protective effect of calcium intakes beyond 700 mg per day, and significant associations were limited to cancers of the distal colon.28 In our study, calcium with vitamin D supplementation was not protective among women with baseline intakes below 800 mg per day, tempering enthusiasm for this explanation. Although our initial analyses of nested case–control studies found lower baseline serum 25-hydroxyvitamin D levels to be associated with an increased risk of colorectal cancer, in contrast to the findings of a previous study,13 we did not find that serum levels modified the effect of the intervention on the outcome.

Our study has several other potential limitations. The calcium doses as well as vitamin D doses we used may have been insufficient to demonstrate a protective effect, particularly given the fraction of participants who were not fully adherent throughout the study. When we began the study, a daily supplement of 400 IU of vitamin D was considered relatively high. Studies published since that time have led some to recommend daily intakes of vitamin D higher than the one we used.29 We evaluated a single regimen and cannot assess whether other formulations or doses would have changed the results.

Since the protocol did not require participants to undergo bowel examinations, some cancers may have been missed. However, the frequency of bowel examinations was very similar in the two groups throughout follow-up. Abdominal pain and a change in bowel habits are common initial manifestations of colorectal cancer that may lead to more aggressive screening30,31; however, the types and frequency of symptoms were similar in the two groups. Annualized rates of invasive colon cancer (0.10 percent) and rectal cancer (0.03 percent) in our study were similar to Surveillance, Epidemiology, and End Results rates for women of corresponding age during the years 1992 through 2002 (0.09 percent and 0.03 percent, respectively).32 Nonetheless, regular or end-of-study colonoscopies may have enabled us to make a more accurate assessment of the effect of calcium with vitamin D supplementation on these tumors.

Two other limitations are the timing of administration of the intervention and the length of follow-up. If the benefit of calcium with vitamin D supplementation is to prevent or slow the progression of colorectal cancer in its early stages and if colorectal cancer has a latency of 10 to 20 years, the average intervention and follow-up of 7 years in our study may have been insufficient to demonstrate an effect. The duration of follow-up was shorter in our trial than in some observational studies that have found a link between calcium and vitamin D intake and the risk of colorectal cancer. Although we did not find a trend toward protection in the later years of follow-up, the ongoing five-year WHI extension study, without intervention, will continue to assess incident colorectal cancers and allow us to identify later effects of this intervention, if they exist.

The strengths of our study include its randomized, double-blind, placebo-controlled design; the large racially and ethnically diverse study population; the comprehensive assessment of risk factors for colorectal cancer at baseline; and the standardized assessment of colorectal-cancer events in a blinded fashion.

In summary, we found that seven years of calcium carbonate plus vitamin D3 supplementation had no effect on the incidence of colorectal cancer in a randomized trial. Although calcium plus vitamin D supplementation may provide some protection against fracture,23 it did not protect against colorectal cancer. The long latency associated with the development of colorectal cancer, in concert with the seven-year duration of the trial, may have contributed to this null finding. However, these results do not provide support for the general use of calcium plus vitamin D supplementation to prevent colorectal cancer.

Supported by the National Heart, Lung, and Blood Institute, Department of Health and Human Services. Many clinical centers received assistance from the General Clinical Research Center program of the National Center for Research Resources. The active study drug and placebo were supplied by GlaxoSmithKline Consumer Healthcare (Pittsburgh).

Dr. Assaf reports being an employee of Pfizer since December 2002 and reports owning stock and having stock options in Pfizer. Dr. Brunner reports being principal investigator of a study funded by the National Cancer Institute of Canada and Pfizer. Dr. O'Sullivan reports receiving grant support from Pfizer-Viracept PK. Dr. Robbins reports having received grants with industry support but without salary support. Dr. Sharma reports having received grant support from Merck and GlaxoSmithKline for an HPV vaccine study. Dr. Hays reports having received lecture fees for a conference sponsored by Procter & Gamble. Dr. Howard reports having received lecture fees from Schering-Plough and serving as a consultant for Merck, the Egg Nutrition Council, and General Mills. Dr. Jackson reports having received consulting fees from Procter & Gamble, lecture fees from Aventis/Procter & Gamble, and grant support from Novartis. Dr. LaCroix reports having received consulting fees from Pfizer, Procter & Gamble, and the Alliance for Better Bone Health and a lecture fee from Schering Plough. Dr. Lewis reports receiving grant support from Pfizer and Novartis. No other potential conflict of interest relevant to this article was reported.

We are indebted to the investigators and staff of the WHI clinical centers, the WHI Clinical Coordinating Center, and the National Heart, Lung, and Blood Institute program office for their dedication and effort; to Rebecca J. Rodabough for her invaluable assistance and expertise in completing the statistical analyses for this article; and to the WHI participants for their extraordinary commitment to the study.

Source Information

Address reprint requests to Dr. Wactawski-Wende at the Department of Social and Preventive Medicine, University at Buffalo, 270 Farber Hall, Buffalo, NY 14214, or at .

The Women's Health Initiative Investigators are listed in Appendix 1. The authors' affiliations are listed in Appendix 2.

Appendix

Appendix 1

The following persons and facilities participated in the WHI study: Program Office: National Heart, Lung, and Blood Institute, Bethesda, Md. — B. Alving, J. Rossouw, L. Pottern, S. Ludlam, J. McGowan, N. Geller, L. Ford; Clinical Coordinating Center: Fred Hutchinson Cancer Research Center, Seattle — R. Prentice, G. Anderson, A. LaCroix, R. Patterson, A. McTiernan, B. Cochrane, J. Hunt, L. Tinker, C. Kooperberg, M. McIntosh, C.Y. Wang, C. Chen, D. Bowen, A. Kristal, J. Stanford, N. Urban, N. Weiss, E. White; Wake Forest University School of Medicine, Winston-Salem, N.C. — S. Shumaker, R. Prineas, M. Naughton; Medical Research Laboratories, Highland Heights, Ky. — E. Stein, P. Laskarzewski; San Francisco Coordinating Center, San Francisco — S.R. Cummings, M. Nevitt, L. Palermo; University of Minnesota, Minneapolis — L. Harnack; Fisher BioServices, Rockville, Md. — F. Cammarata, S. Lindenfelser; University of Washington, Seattle — B. Psaty, S. Heckbert; Clinical Centers: Albert Einstein College of Medicine, Bronx, N.Y. — S. Wassertheil-Smoller, W. Frishman, J. Wylie-Rosett, D. Barad, R. Freeman; Baylor College of Medicine, Houston — J. Hays, R. Young, J. Anderson, S. Lithgow, P. Bray; Brigham and Women's Hospital, Harvard Medical School, Boston — J.E. Manson, J.M. Gaziano, C. Chae, K. Rexrode, C. Solomon; Brown University, Providence, R.I. — A.R. Assaf, C. Wheeler, C. Eaton, M. Cyr; Emory University, Atlanta — L. Phillips, M. Pedersen, O. Strickland, M. Huber, V. Porter; Fred Hutchinson Cancer Research Center, Seattle — S.A.A. Beresford, V.M. Taylor, N.F. Woods, M. Henderson, R. Andersen; George Washington University, Washington, D.C. — J. Hsia, N. Gaba, J. Ascensao; Harbor–UCLA Research and Education Institute, Torrance, Calif. — R. Chlebowski, R. Detrano, A. Nelson, M. Geller; Kaiser Permanente Center for Health Research, Portland, Oreg. — E. Whitlock, P. Elmer, V. Stevens, N. Karanja; Kaiser Permanente Division of Research, Oakland, Calif. — B. Caan, S. Sidney, G. Bailey, J. Hirata; Medical College of Wisconsin, Milwaukee — J. Morley Kotchen, V. Barnabei, T.A. Kotchen, M.C. Gilligan, J. Neuner; MedStar Research Institute/Howard University, Washington, D.C. — B.V. Howard, L. Adams-Campbell, L. Lessin, M. Rainford, G. Uwaifo; Northwestern University, Chicago — L. Van Horn, P. Greenland, J. Khandekar, K. Liu, C. Rosenberg; Rush University Medical Center, Chicago — H. Black, L. Powell, E. Mason; M. Gulati; Stanford Prevention Research Center, Stanford, Calif. — M.L. Stefanick, M.A. Hlatky, B. Chen, R.S. Stafford, S. Mackey; State University of New York at Stony Brook, Stony Brook — D. Lane, I. Granek, W. Lawson, G. San Roman, C. Messina; Ohio State University, Columbus — R. Jackson, R. Harris, E. Paskett, W.J. Mysiw, M. Blumenfeld; University of Alabama at Birmingham, Birmingham — C.E. Lewis, A. Oberman, J.M. Shikany, M. Safford, M. Fouad; University of Arizona, Tucson — T. Bassford, C. Thomson, M. Ko, A. Lopez, C. Ritenbaugh; University at Buffalo, Buffalo, N.Y. — J. Wactawski-Wende, M. Trevisan, E. Smit, S. Graham, J. Chang; University of California at Davis, Sacramento — J. Robbins, S. Yasmeen; University of California at Irvine, Irvine — F.A. Hubbell, G. Frank, N. Wong, N. Greep, B. Monk; University of California at Los Angeles, Los Angeles — H. Judd, D. Heber, R. Elashoff; University of California at San Diego, La Jolla — R.D. Langer, M.H. Criqui, G.T. Talavera, C.F. Garland, M.A. Allison; University of Cincinnati, Cincinnati — M. Gass, S. Wernke; University of Florida, Gainesville — M. Limacher, M. Perri, A. Kaunitz, R.S. Williams, Y. Brinson; University of Hawaii, Honolulu — J.D. Curb, H. Petrovitch, B. Rodriguez, K. Masaki, S. Sharma; University of Iowa, Iowa City — R. Wallace, J. Torner, S. Johnson, L. Snetselaar, J. Robinson; University of Massachusetts, Fallon Clinic, Worcester — J. Ockene, M. Rosal, I. Ockene, R. Yood, P. Aronson; University of Medicine and Dentistry of New Jersey, Newark — N. Lasser, B. Singh, V. Lasser, J. Kostis, P. McGovern; University of Miami, Miami — M.J. O'Sullivan, L. Parker, T. DeSantis, D. Fernandez, P. Caralis; University of Minnesota, Minneapolis — K.L. Margolis, R.H. Grimm, M.F. Perron, C. Bjerk, S. Kempainen; University of Nevada, Reno — R. Brunner, W. Graettinger, V. Oujevolk, M. Bloch; University of North Carolina, Chapel Hill — G. Heiss, P. Haines, D. Ontjes, C. Sueta, E. Wells; University of Pittsburgh, Pittsburgh — L. Kuller, J. Cauley, N.C. Milas; University of Tennessee Health Science Center, Memphis — K.C. Johnson, S. Satterfield, R.W. Ke, S. Connelly, F. Tylavsky; University of Texas Health Science Center, San Antonio — R. Brzyski, R. Schenken, J. Trabal, M. Rodriguez-Sifuentes, C. Mouton; University of Wisconsin, Madison — G.E. Sarto, D. Laube, P. McBride, J. Mares-Perlman, B. Loevinger; Wake Forest University School of Medicine, Winston-Salem, N.C. — D. Bonds, G. Burke, R. Crouse, M. Vitolins, S. Washburn; Wayne State University School of Medicine and Hutzel Hospital, Detroit — S. Hendrix, M. Simon, G. McNeeley; Former Principal Investigators and Project Officers: Baylor College of Medicine, Houston — J. Foreyt; Emory University, Atlanta — D. Hall, S. McNagny, N. Watts; George Washington University, St. Louis — V. Miller; Kaiser Permanent, Oakland, Calif. —R. Hiatt; Kaiser Permanente, Portland, Oreg. — B. Valanis; National Cancer Institute, Bethesda, Md. — C. Clifford (deceased); University of Arizona, Tucson — T. Moon; University of California, Irvine — F. Meyskens, Jr.; University of Cincinnati, Cincinnati — J. Liu; University of Miami, Miami — M. Baum; University of Nevada, Las Vegas — S. Daugherty (deceased); University of North Carolina, Chapel Hill — D. Sheps, Barbara Hulka; University of Tennessee, Memphis — W. Applegate; University of Wisconsin, Milwaukee — C. Allen (deceased); Data and Safety Monitoring Board: J. Wittes (chair), E. Braunwald, M. Chesney, H. Cohen, E. Barrett-Connor, D. DeMets, L. Dunn, J. Dwyer, R.P. Heaney, D. Marson, V. Vogel, L. Walters, S. Yusuf.

Appendix 2

From the University at Buffalo, Buffalo, N.Y. (J.W.-W.); the Medical College of Wisconsin, Milwaukee (J.M.K.); Fred Hutchinson Cancer Research Center, Seattle (G.L.A., R.L.P., C.L.K., A.Z.L.); Memorial Hospital of Rhode Island, Pawtucket (A.R.A.); Pfizer, New London, Conn. (A.R.A.); the University of Nevada School of Medicine, Reno (R.L.B.); the University of Miami, Miami (M.J.O.); the University of Minnesota, Minneapolis (K.L.M.); the University of Massachusetts, Fallon Clinic, Worcester (J.K.O.); Emory University, Atlanta (L. Phillips); the National Heart, Lung, and Blood Institute, Bethesda, Md. (L. Pottern); the University of California at Davis, Sacramento (J.R.); Albert Einstein College of Medicine, Bronx, N.Y. (T.E.R.); the University of Wisconsin, Madison (G.E.S.); the University of Hawaii, Honolulu (S.S.); Stanford Prevention Research Center, Stanford, Calif. (M.L.S.); Northwestern University, Chicago (L.V.H.); the University of Iowa, Iowa City (R.B.W.); Kaiser Permanente Center for Health Research, Portland, Oreg. (E.W.); the University of Arizona, Tucson (T.B.); the University of Washington, Seattle (S.A.A.B.); Rush Medical Center, Chicago (H.R.B.); Wake Forest University School of Medicine, Winston-Salem, N.C. (D.E.B.); the University of Texas Health Science Center, San Antonio (R.G.B.); Kaiser Permanente Division of Research, Oakland, Calif. (B.C.); Los Angeles Biomedical Research Institute at Harbor–UCLA Medical Center, Torrance, Calif. (R.T.C.); the University of Washington School of Nursing, Seattle (B.C.); the University of California at San Diego, La Jolla (C.G., R.D.L.); the University of Cincinnati, Cincinnati (M.G.); Baylor College of Medicine, Houston (J. Hays); the University of North Carolina, Chapel Hill (G.H.); Wayne State University School of Medicine and Hutzel Hospital, Detroit (S.L.H.); MedStar Research Institute, Howard University, Washington, D.C. (B.V.H.); George Washington University Medical Center, Washington, D.C. (J. Hsia); the University of California at Irvine, Irvine (F.A.H.); Ohio State University, Columbus (R.D.J.); the University of Tennessee Health Science Center, Memphis (K.C.J.); the University of California at Los Angeles, Los Angeles (H.J.); the University of Pittsburgh, Pittsburgh (L.H.K.); State University of New York at Stony Brook, Stony Brook (D.S.L.); the University of Medicine and Dentistry of New Jersey, Newark (N.L.L.); the University of Alabama at Birmingham, Birmingham (C.E.L.); the University of Florida, Gainesville (M.C.L.); and Brigham and Women's Hospital and Harvard Medical School, Boston (J.E.M.).

References

References

  1. 1

    Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ. Cancer statistics, 2003. CA Cancer J Clin 2003;53:5-26
    CrossRef | Web of Science | Medline

  2. 2

    Janne PA, Mayer RJ. Chemoprevention of colorectal cancer. N Engl J Med 2000;342:1960-1968
    Full Text | Web of Science | Medline

  3. 3

    Flood A, Peters U, Chatterjee N, Lacey JV Jr, Schairer C, Schatzkin A. Calcium from diet and supplements is associated with reduced risk of colorectal cancer in a prospective cohort of women. Cancer Epidemiol Biomarkers Prev 2005;14:126-132
    Web of Science | Medline

  4. 4

    McCullough ML, Robertson AS, Rodriguez C, et al. Calcium, vitamin D, dairy products, and risk of colorectal cancer in the Cancer Prevention Study II Nutrition Cohort (United States). Cancer Causes Control 2003;14:1-12
    CrossRef | Web of Science | Medline

  5. 5

    Terry P, Baron JA, Bergkvist L, Holmberg L, Wolk A. Dietary calcium-vitamin D intake and risk of colorectal cancer: a prospective cohort study in women. Nutr Cancer 2002;43:39-46
    CrossRef | Web of Science | Medline

  6. 6

    Marcus PM, Newcomb PA. The association of calcium and vitamin D, and colon and rectal cancer in Wisconsin women. Int J Epidemiol 1998;27:788-793
    CrossRef | Web of Science | Medline

  7. 7

    Peters U, Chatterjee N, McGlynn KA, et al. Calcium intake and colorectal adenoma in a US colorectal cancer early detection program. Am J Clin Nutr 2004;80:1358-1365
    Web of Science | Medline

  8. 8

    Kesse E, Boutron-Ruault MC, Norat T, et al. Dietary calcium, phosphorus, vitamin D, dairy products and the risk of colorectal adenoma among French women of the E3N-EPIC prospective study. Int J Cancer 2005;117:137-144
    CrossRef | Web of Science | Medline

  9. 9

    Cho E, Smith-Warner SA, Spiegelman D, et al. Dairy foods, calcium, and colorectal cancer: a pooled analysis of 10 cohort studies. J Natl Cancer Inst 2004;96:1015-1022[Erratum, J Natl Cancer Inst 2004;96:1724.]
    CrossRef | Web of Science | Medline

  10. 10

    Bergsma-Kadijk JA, van't Veer P, Kampman E, Burema J. Calcium does not protect against colorectal neoplasia. Epidemiology 1996;7:590-597
    CrossRef | Web of Science | Medline

  11. 11

    Baron JA, Beach M, Mandel JS, et al. Calcium supplements for the prevention of colorectal adenomas. N Engl J Med 1999;340:101-107
    Free Full Text | Web of Science | Medline

  12. 12

    Bonithon-Kopp C, Kronborg O, Giacosa A, Rath U, Faivre J. Calcium and fibre supplementation in prevention of colorectal adenoma recurrence: a randomised intervention trial. Lancet 2000;356:1300-1306
    CrossRef | Web of Science | Medline

  13. 13

    Grau MV, Baron JA, Sandler RS, et al. Vitamin D, calcium supplementation, and colorectal adenomas: results of a randomized trial. J Natl Cancer Inst 2003;95:1765-1771
    CrossRef | Web of Science | Medline

  14. 14

    Jackson RD, LaCroix AZ, Gass M, et al. Calcium plus vitamin D supplementation and the risk of fractures. N Engl J Med 2006;354:669-683
    Free Full Text | Web of Science | Medline

  15. 15

    Anderson GL, Manson J, Wallace R, et al. Implementation of the Women's Health Initiative study design. Ann Epidemiol 2003;13:Suppl:S5-S17
    CrossRef | Web of Science | Medline

  16. 16

    Hays J, Hunt JR, Hubbell FA, et al. The Women's Health Initiative recruitment methods and results. Ann Epidemiol 2003;13:Suppl:S18-S77
    CrossRef | Web of Science | Medline

  17. 17

    Ritenbaugh C, Patterson RE, Chlebowski RT, et al. The Women's Health Initiative dietary modification trial: overview and baseline characteristics of participants. Ann Epidemiol 2003;13:Suppl:S87-S97
    CrossRef | Web of Science | Medline

  18. 18

    Stefanick ML, Cochrane BB, Hsia J, Barad DH, Liu JH, Johnson SR. The Women's Health Initiative postmenopausal hormone trials: overview and baseline characteristics of participants. Ann Epidemiol 2003;13:Suppl:S78-S86
    CrossRef | Web of Science | Medline

  19. 19

    Jackson RD, LaCroix AZ, Cauley JA, McGowan J. The Women's Health Initiative calcium-vitamin D trial: overview and baseline characteristics of participants. Ann Epidemiol 2003;13:Suppl:S98-S106
    CrossRef | Web of Science | Medline

  20. 20

    Curb JD, McTiernan A, Heckbert SR, et al. Outcomes ascertainment and adjudication methods in the Women's Health Initiative. Ann Epidemiol 2003;13:Suppl:S122-S128
    CrossRef | Web of Science | Medline

  21. 21

    Ries LAG, Eisner MP, Kosary CL. SEER cancer statistics review, 1975-2000. Bethesda, Md.: National Cancer Institute, 2003. (Accessed January 26, 2006, at http://seer.cancer.gov/csr/1975_2000.)

  22. 22

    Cox DR. Regression models and life-tables. J R Stat Soc [B] 1972;34:187-220

  23. 23

    Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer? Int J Epidemiol 1980;9:227-231
    CrossRef | Web of Science | Medline

  24. 24

    Prentice RL, Langer R, Stefanick ML, et al. Combined postmenopausal hormone therapy and cardiovascular disease: toward resolving the discrepancy between observational studies and the Women's Health Initiative clinical trial. Am J Epidemiol 2005;162:404-414
    CrossRef | Web of Science | Medline

  25. 25

    Bialostosky K, Wright JD, Kennedy-Stephenson J, McDowell M, Johnson CL. Dietary intake of macronutrients, micronutrients, and other dietary constituents: United States, 1988–94. Vital and health statistics. Series 11. No. 245. Hyattsville, Md.: National Center for Health Statistics, July 2002. (DHHS publication no. (PHS) 2002-1695.)

  26. 26

    Food and Nutrition Board, Institute of Medicine. Dietary reference intakes: for calcium, phosphorous, magnesium, vitamin D, and fluoride. Washington, D.C.: National Academy Press, 1997.

  27. 27

    Ervin RB, Wang C-Y, Wright JD, Kennedy-Stephenson J. Dietary intake of selected minerals for the United States population: 1999–2000. Advance data from vital and health statistics. No. 341. Hyattsville, Md.: National Center for Health Statistics, 2004. (DHHS publication no. (PHS) 2004-1250 04-0304.)

  28. 28

    Wu K, Willett WC, Fuchs CS, Colditz GA, Giovannucci EL. Calcium intake and risk of colon cancer in women and men. J Natl Cancer Inst 2002;94:437-446
    CrossRef | Web of Science | Medline

  29. 29

    Gorham ED, Garland CF, Garland FC, et al. Vitamin D and prevention of colorectal cancer. J Steroid Biochem Mol Biol 2005;97:179-194
    CrossRef | Web of Science | Medline

  30. 30

    Majumdar SR, Fletcher RH, Evans AT. How does colorectal cancer present? Symptoms, duration, and clues to location. Am J Gastroenterol 1999;94:3039-3045
    CrossRef | Web of Science | Medline

  31. 31

    Mor V, Masterson-Allen S, Goldberg R, Guadagnoli E, Wool MS. Pre-diagnostic symptom recognition and help seeking among cancer patients. J Community Health 1990;15:253-266
    CrossRef | Medline

  32. 32

    National Cancer Institute. SEER incidence statistics. (Accessed January 26, 2006, at http://www.seer.cancer.gov/canques/incidence.html.)

Citing Articles (303)

Citing Articles

  1. 1

    Doris Maria Hummel, Ursula Thiem, Julia Höbaus, Ildiko Mesteri, Lukas Gober, Caroline Stremnitzer, João Graça, Barbara Obermayer-Pietsch, Enikö Kallay. (2013) Prevention of preneoplastic lesions by dietary vitamin D in a mouse model of colorectal carcinogenesis. The Journal of Steroid Biochemistry and Molecular Biology 136, 284-288

  2. 2

    Xi Emily Zheng, Seth Lipka, Ting Li, Ghulamullah Shahzad, Evan Levine, Raymond Vlacancich, Umeko Takeshige, Paul Mustacchia. (2013) The relationship of vitamin D status, smoking, and colorectal adenoma: A retrospective study in an ethnically diverse community. The Journal of Steroid Biochemistry and Molecular Biology 136, 280-283

  3. 3

    Abul Kalam Azad, Isabelle Bairati, Xin Qiu, Huayi Huang, Dangxiao Cheng, Geoffrey Liu, Francois Meyer, Araba Adjei, Wei Xu. (2013) Genetic sequence variants in vitamin D metabolism pathway genes, serum vitamin D level and outcome in head and neck cancer patients. International Journal of Cancer 132:11, 2520-2527

  4. 4

    Arash Hossein-nezhad, Michael F. Holick. (2013) Vitamin D for Health: A Global Perspective. Mayo Clinic Proceedings

  5. 5

    Garnet L. Anderson. (2013) A Statistical Perspective on Prevention Trials: A View from the Women’s Health Initiative. Statistics in Biosciences

  6. 6

    David B Buller, Marianne Berwick, James Shane, Ilima Kane, Kathleen Lantz, Mary Klein Buller. (2013) User-centered development of a smart phone mobile application delivering personalized real-time advice on sun protection. Translational Behavioral Medicine

  7. 7

    Sarah M. Bristow, Mark J. Bolland, Graeme S. MacLennan, Alison Avenell, Andrew Grey, Greg D. Gamble, Ian R. Reid. (2013) Calcium supplements and cancer risk: a meta-analysis of randomised controlled trials. British Journal of Nutrition1-10

  8. 8

    Rui Wang, James H. Ware. (2013) Detecting Moderator Effects Using Subgroup Analyses. Prevention Science 14:2, 111-120

  9. 9

    Han van der Rhee, Jan Willem Coebergh, Esther de Vries. (2013) Is prevention of cancer by sun exposure more than just the effect of vitamin D? A systematic review of epidemiological studies. European Journal of Cancer 49:6, 1422-1436

  10. 10

    Sathish K.R. Padi, Qunshu Zhang, Youcef M. Rustum, Carl Morrison, Bin Guo. (2013) MicroRNA-627 Mediates the Epigenetic Mechanisms of Vitamin D to Suppress Proliferation of Human Colorectal Cancer Cells and Growth of Xenograft Tumors in Mice. Gastroenterology

  11. 11

    C. Leyssens, L. Verlinden, A. Verstuyf. (2013) Antineoplastic effects of 1,25(OH)2D3 and its analogs in breast, prostate and colorectal cancer. Endocrine Related Cancer 20:2, R31-R47

  12. 12

    Jung Eun Lee. (2013) Vitamin D and Colorectal Cancer Prevention: A Review of Epidemiologic Studies. Current Nutrition Reports 2:1, 27-36

  13. 13

    Katia Lofano, Mariabeatrice Principi, Maria Principia Scavo, Maria Pricci, Enzo Ierardi, Alfredo Di Leo. (2013) Dietary Lifestyle and Colorectal Cancer Onset, Recurrence, and Survival: Myth or Reality?. Journal of Gastrointestinal Cancer 44:1, 1-11

  14. 14

    Shahzaib Ahmad, Tahseen A. Chowdhury, Barbara J. Boucher. (2013) Diabetes and cancer: Could vitamin D provide the link?. Journal of Diabetes and its Complications 27:2, 184-190

  15. 15

    Pawel Pludowski, Michael F. Holick, Stefan Pilz, Carol L. Wagner, Bruce W. Hollis, William B. Grant, Yehuda Shoenfeld, Elisabeth Lerchbaum, David J. Llewellyn, Katharina Kienreich, Maya Soni. (2013) Vitamin D effects on musculoskeletal health, immunity, autoimmunity, cardiovascular disease, cancer, fertility, pregnancy, dementia and mortality—A review of recent evidence. Autoimmunity Reviews

  16. 16

    R. L. Prentice, M. B. Pettinger, R. D. Jackson, J. Wactawski-Wende, A. Z. LaCroix, G. L. Anderson, R. T. Chlebowski, J. E. Manson, L. Horn, M. Z. Vitolins, M. Datta, E. S. LeBlanc, J. A. Cauley, J. E. Rossouw. (2013) Health risks and benefits from calcium and vitamin D supplementation: Women's Health Initiative clinical trial and cohort study. Osteoporosis International 24:2, 567-580

  17. 17

    Renate M Winkels, Fränzel JB van Duijnhoven, Renate C Heine-Bröring, Ellen Kampman. (2013) Diet and colorectal cancer risk and survival. Colorectal Cancer 2:1, 43-50

  18. 18

    Mohammed A. Islam. (2013) An Elective Course on the Basic and Clinical Sciences Aspects of Vitamins and Minerals. American Journal of Pharmaceutical Education 77:1, 17

  19. 19

    J. Doley. Minerals and Older Adults. In: Bioactive Food as Dietary Interventions for the Aging Population. Elsevier, 2013:335-356.

  20. 20

    M.J. Marian. Vitamins and Older Adults. In: Bioactive Food as Dietary Interventions for the Aging Population. Elsevier, 2013:47-60.

  21. 21

    Heather Patrick, Karen Glanz. Cancer Prevention for Women. In: Women and Health. Elsevier, 2013:1231-1241.

  22. 22

    Corinne E. Joshu, Edward Giovannucci, Elizabeth A. Platz. Colorectal Cancer in Women. In: Women and Health. Elsevier, 2013:1209-1219.

  23. 23

    Shari S. Bassuk, JoAnn E. Manson. Vitamin D and Disease Prevention in Women. In: Women and Health. Elsevier, 2013:915-928.

  24. 24

    Katherine D. Crew. (2013) Vitamin D: Are We Ready to Supplement for Breast Cancer Prevention and Treatment?. ISRN Oncology 2013, 1-22

  25. 25

    M.-T. Leccia. (2013) Peau, soleil et vitamine D : réalités et controverses. Annales de Dermatologie et de Vénéréologie

  26. 26

    Hyun Ah Park, Soo Young Kim. (2013) Recent advance on vitamin D. Journal of the Korean Medical Association 56:4, 310

  27. 27

    Cintia Milani, Maria Lucia Hirata Katayama, Eduardo Carneiro de Lyra, JoEllen Welsh, Laura Tojeiro Campos, M Mitzi Brentani, Maria do Socorro Maciel, Rosimeire Aparecida Roela, Paulo Roberto del Valle, João Carlos Guedes Sampaio Góes, Suely Nonogaki, Rodrigo Esaki Tamura, Maria Aparecida Azevedo Koike Folgueira. (2013) Transcriptional effects of 1,25 dihydroxyvitamin D3 physiological and supra-physiological concentrations in breast cancer organotypic culture. BMC Cancer 13:1, 119

  28. 28

    Aliana Guerrieri-Gonzaga, Sara Gandini. (2013) Vitamin D and overall mortality. Pigment Cell & Melanoma Research 26:1, 16-28

  29. 29

    Suneil Malik, Lei Fu, David James Juras, Mohamed Karmali, Betty Y. L. Wong, Agnes Gozdzik, David E. C. Cole. (2013) Common variants of the vitamin D binding protein gene and adverse health outcomes. Critical Reviews in Clinical Laboratory Sciences 50:1, 1-22

  30. 30

    Joel H Rubenstein. (2012) Editorial: Shedding Some Light on the Etiology of Adenocarcinomas of the Esophagus and Gastric Cardia. The American Journal of Gastroenterology 107:12, 1814-1816

  31. 31

    Rebecca C. Rossom, Mark A. Espeland, JoAnn E. Manson, Maurice W. Dysken, Karen C. Johnson, Dorothy S. Lane, Erin S. LeBlanc, Frank A. Lederle, Kamal H. Masaki, Karen L. Margolis. (2012) Calcium and Vitamin D Supplementation and Cognitive Impairment in the Women's Health Initiative. Journal of the American Geriatrics Society 60:12, 2197-2205

  32. 32

    W. B. Grant. (2012) Re: "The Influence of Health and Lifestyle Characteristics on the Relation of Serum 25-Hydroxyvitamin D With Risk of Colorectal and Breast Cancer in Postmenopausal Women". American Journal of Epidemiology 176:9, 838-838

  33. 33

    Helena Orell-Kotikangas, Ursula Schwab, Pia Österlund, Kauko Saarilahti, Outi Mäkitie, Antti A. Mäkitie. (2012) High prevalence of vitamin D insufficiency in patients with head and neck cancer at diagnosis. Head & Neck 34:10, 1450-1455

  34. 34

    Caroline Hwang, Viveca Ross, Uma Mahadevan. (2012) Micronutrient deficiencies in inflammatory bowel disease: From A to zinc. Inflammatory Bowel Diseases 18:10, 1961-1981

  35. 35

    Gabriela Picotto, Ana C. Liaudat, Luciana Bohl, Nori Tolosa de Talamoni. (2012) Molecular Aspects of Vitamin D Anticancer Activity. Cancer Investigation120910114607003

  36. 36

    Heidi Wolden-Kirk, Conny Gysemans, Annemieke Verstuyf, Chantal Mathieu. (2012) Extraskeletal Effects of Vitamin D. Endocrinology and Metabolism Clinics of North America 41:3, 571-594

  37. 37

    C A Thomson, B C Wertheim, M Hingle, L Wang, M L Neuhouser, Z Gong, L Garcia, M L Stefanick, J E Manson. (2012) Alcohol consumption and body weight change in postmenopausal women: results from the Women's Health Initiative. International Journal of Obesity 36:9, 1158-1164

  38. 38

    Chris R. Cardwell, Christian C. Abnet, Philip Veal, Carmel M. Hughes, Marie M. Cantwell, Liam J. Murray. (2012) Exposure to oral bisphosphonates and risk of cancer. International Journal of Cancer 131:5, E717-E725

  39. 39

    Susan T. Mayne, Leah M. Ferrucci, Brenda Cartmel. (2012) Lessons Learned from Randomized Clinical Trials of Micronutrient Supplementation for Cancer Prevention. Annual Review of Nutrition 32:1, 369-390

  40. 40

    Timothy J. Key, Paul N. Appleby, Gabriel Masset, Eric J. Brunner, Janet E. Cade, Darren C. Greenwood, Alison M. Stephen, Diana Kuh, Amit Bhaniani, Natasha Powell, Kay-Tee Khaw. (2012) Vitamins, minerals, essential fatty acids and colorectal cancer risk in the United Kingdom Dietary Cohort Consortium. International Journal of Cancer 131:3, E320-E325

  41. 41

    M. Garg, J. S. Lubel, M. P. Sparrow, S. G. Holt, P. R. Gibson. (2012) Review article: vitamin D and inflammatory bowel disease - established concepts and future directions. Alimentary Pharmacology & Therapeutics 36:4, 324-344

  42. 42

    William Jacot, Stéphane Pouderoux, Simon Thezenas, Angélique Chapelle, Jean-Pierre Bleuse, Gilles Romieu, Pierre-Jean Lamy. (2012) Increased prevalence of vitamin D insufficiency in patients with breast cancer after neoadjuvant chemotherapy. Breast Cancer Research and Treatment 134:2, 709-717

  43. 43

    S. Hatse, D. Lambrechts, A. Verstuyf, A. Smeets, B. Brouwers, T. Vandorpe, O. Brouckaert, G. Peuteman, A. Laenen, L. Verlinden, C. Kriebitzsch, A.-S. Dieudonne, R. Paridaens, P. Neven, M.-R. Christiaens, R. Bouillon, H. Wildiers. (2012) Vitamin D status at breast cancer diagnosis: correlation with tumor characteristics, disease outcome, and genetic determinants of vitamin D insufficiency. Carcinogenesis 33:7, 1319-1326

  44. 44

    Jacqueline S. Danik, JoAnn E. Manson. (2012) Vitamin D and Cardiovascular Disease. Current Treatment Options in Cardiovascular Medicine

  45. 45

    F. Pereira, M. J. Larriba, A. Munoz. (2012) Vitamin D and colon cancer. Endocrine Related Cancer 19:3, R51-R71

  46. 46

    Qi Dai, Robert Sandler, Elizabeth Barry, Robert Summers, Maria Grau, John Baron. (2012) Calcium, Magnesium, and Colorectal Cancer. Epidemiology 23:3, 504-505

  47. 47

    Jose J. G. Marin, Fermin Sanchez de Medina, Beatriz Castaño, Luis Bujanda, Marta R. Romero, Olga Martinez-Augustin, Rosario Del Moral-Avila, Oscar Briz. (2012) Chemoprevention, chemotherapy, and chemoresistance in colorectal cancer. Drug Metabolism Reviews 44:2, 148-172

  48. 48

    Neeraj Narula, John K. Marshall. (2012) Management of inflammatory bowel disease with vitamin D: Beyond bone health. Journal of Crohn's and Colitis 6:4, 397-404

  49. 49

    M. E. Martinez, E. T. Jacobs, J. A. Baron, J. R. Marshall, T. Byers. (2012) Dietary Supplements and Cancer Prevention: Balancing Potential Benefits Against Proven Harms. JNCI Journal of the National Cancer Institute

  50. 50

    Tanya M. Wildes. Cancer and Ageing. In: Pathy's Principles and Practice of Geriatric Medicine. John Wiley & Sons, Ltd, 2012:1317-1331.

  51. 51

    Stuart T. Haines, Sharon K. Park. (2012) Vitamin D Supplementation: What's Known, What to Do, and What's Needed. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 32:4, 354-382

  52. 52

    Yiqing Song, Lu Wang. (2012) Vitamin D and Cardiometabolic Disease: From Observation to Intervention. Current Nutrition Reports

  53. 53

    Prevention and Mitigation of Late Adverse Effects of High Radiation Doses. In: Radiation Injury Prevention and Mitigation in Humans. CRC Press, 2012:169-200.

  54. 54

    Jennifer G. Powers, Barbara A. Gilchrest. (2012) What You and Your Patients Need to Know About Vitamin D. Seminars in Cutaneous Medicine and Surgery 31:1, 2-10

  55. 55

    Ashwin N. Ananthakrishnan, Hamed Khalili, Leslie M. Higuchi, Ying Bao, Joshua R. Korzenik, Edward L. Giovannucci, James M. Richter, Charles S. Fuchs, Andrew T. Chan. (2012) Higher Predicted Vitamin D Status Is Associated With Reduced Risk of Crohn's Disease. Gastroenterology 142:3, 482-489

  56. 56

    M. L. Neuhouser, J. E. Manson, A. Millen, M. Pettinger, K. Margolis, E. T. Jacobs, J. M. Shikany, M. Vitolins, L. Adams-Campbell, S. Liu, E. LeBlanc, K. C. Johnson, J. Wactawski-Wende. (2012) The Influence of Health and Lifestyle Characteristics on the Relation of Serum 25-Hydroxyvitamin D With Risk of Colorectal and Breast Cancer in Postmenopausal Women. American Journal of Epidemiology

  57. 57

    Suzanne Dixon. (2012) Nutrition in Complementary and Alternative Medicine. Seminars in Oncology Nursing 28:1, 75-84

  58. 58

    Bruce W. Hollis. (2012) Assessment and Interpretation of Circulating 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D in the Clinical Environment. Rheumatic Disease Clinics of North America 38:1, 29-44

  59. 59

    Michael F. Holick. (2012) Vitamin D: Extraskeletal Health. Rheumatic Disease Clinics of North America 38:1, 141-160

  60. 60

    J.-J. Body, P. Bergmann, S. Boonen, J.-P. Devogelaer, E. Gielen, S. Goemaere, J.-M. Kaufman, S. Rozenberg, J.-Y. Reginster. (2012) Extraskeletal benefits and risks of calcium, vitamin D and anti-osteoporosis medications. Osteoporosis International 23:S1, 1-23

  61. 61

    Neil Binkley, Rekha Ramamurthy, Diane Krueger. (2012) Low Vitamin D Status: Definition, Prevalence, Consequences, and Correction. Rheumatic Disease Clinics of North America 38:1, 45-59

  62. 62

    Heather Greenlee. (2012) Natural Products for Cancer Prevention. Seminars in Oncology Nursing 28:1, 29-44

  63. 63

    Ben Schöttker, Dorothee Ball, Carolin Gellert, Hermann Brenner. (2012) Serum 25-hydroxyvitamin D levels and overall mortality. A systematic review and meta-analysis of prospective cohort studies. Ageing Research Reviews

  64. 64

    Hajo Zeeb. (2012) Vitamin D and Cancer Prevention. Current Nutrition Reports

  65. 65

    Barbara C. Pence, Eric J. Belasco, Conrad P. Lyford. (2012) Prevention of Colorectal Cancer by Aspirin and/or Calcium: Efficacy, Mechanisms, and Cost Effectiveness. Current Colorectal Cancer Reports

  66. 66

    N. Gueli, W. Verrusio, A. Linguanti, F. Di Maio, A. Martinez, B. Marigliano, M. Cacciafesta. (2012) Vitamin D: drug of the future. A new therapeutic approach. Archives of Gerontology and Geriatrics 54:1, 222-227

  67. 67

    Lemuel A. Moyé. (2012) Rudiments of Subgroup Analyses. Progress in Cardiovascular Diseases 54:4, 338-342

  68. 68

    Charles D. Blanke, Douglas O. Faigel. Neoplasms of the Small and Large Intestine. In: Goldman's Cecil Medicine. Elsevier, 2012:1278-1289.

  69. 69

    Marius Racovan, Brian Walitt, Christopher E. Collins, Mary Pettinger, Christine G. Parks, James M. Shikany, Jean Wactawski-Wende, JoAnn E. Manson, Larry Moreland, Nicole Wright, Rebecca Jackson, Barbara V. Howard. (2011) Calcium and vitamin D supplementation and incident rheumatoid arthritis: the Women’s Health Initiative Calcium plus Vitamin D trial. Rheumatology International

  70. 70

    C. Giardina, J. P. Madigan, C. A. Godman Tierney, B. Brenner, D. W. Rosenberg. (2011) Vitamin D resistance and colon cancer prevention. Carcinogenesis

  71. 71

    John Milner. Bioactive Food Components and the U-Shaped Health Conundrum. In: Nutritional Genomics. CRC Press, 2011:285-300.

  72. 72

    Adolfo Díez Pérez. (2011) Suplementos de vitamina D. Las dosis recomendadas son insuficientes. Medicina Clínica

  73. 73

    Simone Mocellin. (2011) Vitamin D and cancer: Deciphering the truth. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1816:2, 172-178

  74. 74

    K. L. Margolis, L. W. Martin, R. M. Ray, T. J. Kerby, M. A. Allison, J. D. Curb, T. A. Kotchen, S. Liu, S. Wassertheil-Smoller, J. E. Manson, . (2011) A Prospective Study of Serum 25-Hydroxyvitamin D Levels, Blood Pressure, and Incident Hypertension in Postmenopausal Women. American Journal of Epidemiology

  75. 75

    Michele Barone, Katia Lofano, Nicola Tullio, Raffaele Licino, Francesca Albano, Alfredo Leo. (2011) Dietary, Endocrine, and Metabolic Factors in the Development of Colorectal Cancer. Journal of Gastrointestinal Cancer

  76. 76

    Eleni Linos, Elizabeth Keiser, Matthew Kanzler, Kristin L. Sainani, Wayne Lee, Eric Vittinghoff, Mary-Margaret Chren, Jean Y. Tang. (2011) Sun protective behaviors and vitamin D levels in the US population: NHANES 2003–2006. Cancer Causes & Control

  77. 77

    Amy A. Irving, Richard B. Halberg, Dawn M. Albrecht, Lori A. Plum, Kathleen J. Krentz, Linda Clipson, Norman Drinkwater, James M. Amos-Landgraf, William F. Dove, Hector F. DeLuca. (2011) Supplementation by vitamin D compounds does not affect colonic tumor development in vitamin D sufficient murine models. Archives of Biochemistry and Biophysics 515:1-2, 64-71

  78. 78

    Bruce W. Hollis. (2011) Short-term and long-term consequences and concerns regarding valid assessment of vitamin D deficiency. Current Opinion in Clinical Nutrition and Metabolic Care 14:6, 598-604

  79. 79

    Christoph Domarus, Jonathan Brown, Florian Barvencik, Michael Amling, Pia Pogoda. (2011) How Much Vitamin D Do We Need for Skeletal Health?. Clinical Orthopaedics and Related Research® 469:11, 3127-3133

  80. 80

    Michael S. Simon, Carol A. Rosenberg, Rebecca J. Rodabough, Phillip Greenland, Ira Ockene, Hemant K. Roy, Dorothy S. Lane, Jane A. Cauley, Janardan Khandekar. (2011) Prospective Analysis of Association Between Use of Statins or Other Lipid-Lowering Agents and Colorectal Cancer Risk. Annals of Epidemiology

  81. 81

    Bart J. Van der Schueren, Annemieke Verstuyf, Chantal Mathieu. (2011) Straight from D-Heart. Current Opinion in Lipidology1

  82. 82

    Robert Skully, Aroob Shanaah Saleh. (2011) Aging and the Effects of Vitamins and Supplements. Clinics in Geriatric Medicine 27:4, 591-607

  83. 83

    (2011) Design, history and results of the Thiazolidinedione Intervention with vitamin D Evaluation (TIDE) randomised controlled trial. Diabetologia

  84. 84

    Sung Noh Hong, Jeong Hwan Kim, Won Hyeok Choe, Sun-Young Lee, Dong Choon Seol, Hee-Won Moon, Mina Hur, Yeo-Min Yun, In Kyung Sung, Hyung Seok Park, Chan Sup Shim. (2011) Circulating Vitamin D and Colorectal Adenoma in Asymptomatic Average-Risk Individuals Who Underwent First Screening Colonoscopy: A Case–Control Study. Digestive Diseases and Sciences

  85. 85

    JoAnn E. Manson, Shari S. Bassuk, I-Min Lee, Nancy R. Cook, Michelle A. Albert, David Gordon, Elaine Zaharris, Jean G. MacFadyen, Eleanor Danielson, Jennifer Lin, Shumin M. Zhang, Julie E. Buring. (2011) The VITamin D and OmegA-3 TriaL (VITAL): Rationale and design of a large randomized controlled trial of vitamin D and marine omega-3 fatty acid supplements for the primary prevention of cancer and cardiovascular disease. Contemporary Clinical Trials

  86. 86

    Matteo Lazzeroni, Sara Gandini, Matteo Puntoni, Bernardo Bonanni, Alessandra Gennari, Andrea DeCensi. (2011) The science behind vitamins and natural compounds for breast cancer prevention. Getting the most prevention out of it. The Breast 20, S36-S41

  87. 87

    Paul Lee. (2011) Vitamin D metabolism and deficiency in critical illness. Best Practice & Research Clinical Endocrinology & Metabolism 25:5, 769-781

  88. 88

    Robert Scragg. (2011) Vitamin D and public health: an overview of recent research on common diseases and mortality in adulthood. Public Health Nutrition 14:09, 1515-1532

  89. 89

    Xuehong Zhang, Edward Giovannucci. (2011) Calcium, vitamin D and colorectal cancer chemoprevention. Best Practice & Research Clinical Gastroenterology 25:4-5, 485-494

  90. 90

    Robert L. Brunner, Jean Wactawski-Wende, Bette J. Caan, Barbara B. Cochrane, Rowan T. Chlebowski, Margery L. S. Gass, Elizabeth T. Jacobs, Andrea Z. LaCroix, Dorothy Lane, Joseph Larson, Karen L. Margolis, Amy E. Millen, Gloria E. Sarto, Mara Z. Vitolins, Robert B. Wallace. (2011) The Effect of Calcium plus Vitamin D on Risk for Invasive Cancer: Results of the Women's Health Initiative (WHI) Calcium Plus Vitamin D Randomized Clinical Trial. Nutrition and Cancer 63:6, 827-841

  91. 91

    Stefania Makariou, Evangelos N. Liberopoulos, Moses Elisaf, Anna Challa. (2011) Novel roles of vitamin D in disease: What is new in 2011?. European Journal of Internal Medicine 22:4, 355-362

  92. 92

    T. Dinizulu, D. Griffin, J. Carey, E. Mulkerrin. (2011) Vitamin D supplementation versus combined calcium and vitamin D in older female patients — An observational study. The journal of nutrition, health & aging 15:8, 605-608

  93. 93

    Goran Bjelakovic, Lise Lotte Gluud, Dimitrinka Nikolova, Kate Whitfield, Jørn Wetterslev, Rosa G Simonetti, Marija Bjelakovic, Christian Gluud, Goran Bjelakovic. Vitamin D supplementation for prevention of mortality in adults. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2011.

  94. 94

    Camille E Powe, Catherine Ricciardi, Anders H Berg, Delger Erdenesanaa, Gina Collerone, Elizabeth Ankers, Julia Wenger, S Ananth Karumanchi, Ravi Thadhani, Ishir Bhan. (2011) Vitamin D-binding protein modifies the vitamin D-bone mineral density relationship. Journal of Bone and Mineral Research 26:7, 1609-1616

  95. 95

    David Z.J. Chu, Michael A. Hussey, David S. Alberts, Frank L. Meyskens, Cecilia M. Fenoglio-Preiser, Saul E. Rivkin, Glenn M. Mills, Jeffrey K. Giguere, Charles D. Blanke, Gary E. Goodman. (2011) Colorectal Chemoprevention Pilot Study (SWOG-9041), Randomized and Placebo Controlled: The Importance of Multiple Luminal Lesions. Clinical Colorectal Cancer

  96. 96

    E. M. Stein, E. Shane. (2011) Vitamin D in organ transplantation. Osteoporosis International 22:7, 2107-2118

  97. 97

    Michal L Melamed, JoAnn E Manson. (2011) Vitamin D and cardiovascular disease and cancer: not too much and not too little? The need for clinical trials. Women's Health 7:4, 419-424

  98. 98

    Timothy J. Key. (2011) Diet, insulin-like growth factor-1 and cancer risk. Proceedings of the Nutrition Society1-4

  99. 99

    Tom D. Thacher, Bart L. Clarke. (2011) Weighing the Evidence Linking UVB Irradiance, Vitamin D, and Cancer Risk–reply–I. Mayo Clinic Proceedings 86:4, 363

  100. 100

    Sinead Field, Julia A. Newton-Bishop. (2011) Melanoma and vitamin D. Molecular Oncology 5:2, 197-214

  101. 101

    Sara Gandini, Mathieu Boniol, Jari Haukka, Graham Byrnes, Brian Cox, Mary Jane Sneyd, Patrick Mullie, Philippe Autier. (2011) Meta-analysis of observational studies of serum 25-hydroxyvitamin D levels and colorectal, breast and prostate cancer and colorectal adenoma. International Journal of Cancer 128:6, 1414-1424

  102. 102

    S. J. Weinstein, K. Yu, R. L. Horst, J. Ashby, J. Virtamo, D. Albanes. (2011) Serum 25-Hydroxyvitamin D and Risks of Colon and Rectal Cancer in Finnish Men. American Journal of Epidemiology 173:5, 499-508

  103. 103

    Kevin Fiscella, Paul Winters, Daniel Tancredi, Samantha Hendren, Peter Franks. (2011) Racial disparity in death from colorectal cancer. Cancer 117:5, 1061-1069

  104. 104

    Laura A.G. Armas, Robert P. Heaney. (2011) Vitamin D: The Iceberg Nutrient. Journal of Renal Nutrition 21:2, 134-139

  105. 105

    G. O’Malley, E. Mulkerrin. (2011) Vitamin D insufficiency: a common and treatable problem in the Irish population. Irish Journal of Medical Science 180:1, 7-13

  106. 106

    Sandeep Krishnan, Jacqueline L Wolf. (2011) Colorectal cancer screening and prevention in women. Women's Health 7:2, 213-226

  107. 107

    Aruna V. Krishnan, David Feldman. (2011) Mechanisms of the Anti-Cancer and Anti-Inflammatory Actions of Vitamin D. Annual Review of Pharmacology and Toxicology 51:1, 311-336

  108. 108

    Ossama Allam, Diane Bahuaud, Sylviane Taché, Nathalie Naud, Denis E. Corpet, Fabrice H. F. Pierre. (2011) Calcium carbonate suppresses haem toxicity markers without calcium phosphate side effects on colon carcinogenesis. British Journal of Nutrition 105:03, 384-392

  109. 109

    Maria Shin, Christina Minden. (2011) Evaluation of the Effectiveness of Cholecalciferol in Long-Term Care Elderly Patients with Hypovitaminosis D. The Consultant Pharmacist 26:2, 101-107

  110. 110

    Marie Courbebaisse, Dominique Prié, Jean-Claude Souberbielle, Eric Thervet, Gérard Friedlander. (2011) Vitamine D : un champ qui s’élargit. Revue Francophone des Laboratoires 2011:429, 32-35

  111. 111

    Cindy D Davis, John A Milner. (2011) Vitamin D and colon cancer. Expert Review of Gastroenterology & Hepatology 5:1, 67-81

  112. 112

    Jann Arends. (2011) Vitamin D in Oncology. Forschende Komplementärmedizin / Research in Complementary Medicine 18:4, 2-2

  113. 113

    Ross L. Prentice. Statistical Methods and Challenges in Epidemiology and Biomedical Research. In: Essential Statistical Methods for Medical Statistics. Elsevier, 2011:1-26.

  114. 114

    Edward Giovannucci. The Epidemiology of Vitamin D and Cancer Risk. In: Vitamin D. Elsevier, 2011:1569-1590.

  115. 115

    Olivia I. Okereke, JoAnn E. Manson. The VITamin D and OmegA-3 TriaL (VITAL). In: Vitamin D. Elsevier, 2011:2043-2055.

  116. 116

    Roger Bouillon. How to Define Optimal Vitamin D Status. In: Vitamin D. Elsevier, 2011:1067-1088.

  117. 117

    Julie Fox, Barry Peters, Manyu Prakash, Jose Arribas, Andrew Hill, Christiane Moecklinghoff. (2011) Improvement in Vitamin D Deficiency Following Antiretroviral Regime Change: Results from the MONET Trial. AIDS Research and Human Retroviruses 27:1, 29-34

  118. 118

    Henry W. Lim, Wenfei Xie, Darrell S. Rigel. Vitamin D and UV. In: Cancer of the Skin. Elsevier, 2011:650-656.

  119. 119

    Animesh Pardanani, Matthew T. Drake, Christy Finke, Terra L. Lasho, Shaina A. Rozell, Thitina Jimma, Ayalew Tefferi. (2011) Vitamin D insufficiency in myeloproliferative neoplasms and myelodysplastic syndromes: Clinical correlates and prognostic studies. American Journal of Hematologyn/a-n/a

  120. 120

    Rowan T. Chlebowski, Karen C. Johnson, Dorothy Lane, Mary Pettinger, Charles L. Kooperberg, Jean Wactawski-Wende, Tom Rohan, Mary Jo O'Sullivan, Shagufta Yasmeen, Robert A. Hiatt, James M. Shikany, Mara Vitolins, Janu Khandekar, F. Allan Hubbell. (2011) 25-Hydroxyvitamin D concentration, vitamin D intake and joint symptoms in postmenopausal women. Maturitas 68:1, 73-78

  121. 121

    Stephanie R. Downing, Emmanouil P. Pappou, Nita Ahuja. Behavior and Dietary Modification in the Prevention of Colon Cancer. In: Early Diagnosis and Treatment of Cancer Series: Colorectal Cancer. Elsevier, 2011:47-64.

  122. 122

    Bruce W. Hollis. Detection of Vitamin D and Its Major Metabolites. In: Vitamin D. Elsevier, 2011:823-844.

  123. 123

    Rowan T Chlebowski. (2011) Vitamin D and breast cancer: interpreting current evidence. Breast Cancer Research 13:4, 217

  124. 124

    Michael F. Holick. (2011) The D-Batable Institute of Medicine Report: A D-Lightful Perspective. Endocrine Practice 17:1, 143-149

  125. 125

    R K Van Laar. (2010) An online gene expression assay for determining adjuvant therapy eligibility in patients with stage 2 or 3 colon cancer. British Journal of Cancer 103:12, 1852-1857

  126. 126

    Lori A. Plum, Hector F. DeLuca. (2010) Vitamin D, disease and therapeutic opportunities. Nature Reviews Drug Discovery 9:12, 941-955

  127. 127

    Graham A. Colditz. (2010) Overview of the Epidemiology Methods and Applications: Strengths and Limitations of Observational Study Designs. Critical Reviews in Food Science and Nutrition 50:sup1, 10-12

  128. 128

    Ramesh Arasaradnam, K Bardhan. Diet, Epigenetics, and Colonic Fermentation and Their Role in Colorectal Cancer. In: Bioactive Foods and Extracts. CRC Press, 2010:427-439.

  129. 129

    Nasr Anaizi. (2010) Rediscovering vitamin D. Libyan Journal of Medicine 5:0,

  130. 130

    William B. Grant. (2010) Relation between prediagnostic serum 25-hydroxyvitamin D level and incidence of breast, colorectal, and other cancers. Journal of Photochemistry and Photobiology B: Biology 101:2, 130-136

  131. 131

    Mona Shahriari, Philip E. Kerr, Karren Slade, Jane E. Grant-Kels. (2010) Vitamin D and the skin. Clinics in Dermatology 28:6, 663-668

  132. 132

    Lini Alappat, Michael Valerio, Atif B. Awad. (2010) Effect of vitamin D and β-sitosterol on immune function of macrophages. International Immunopharmacology 10:11, 1390-1396

  133. 133

    Aaron J. Weiss, Azi Lipshtat, Jeffrey I. Mechanick. (2010) A systems approach to bone pathophysiology. Annals of the New York Academy of Sciences 1211:1, 9-24

  134. 134

    Stefan Pilz, Andreas Tomaschitz. (2010) Role of vitamin D in arterial hypertension. Expert Review of Cardiovascular Therapy 8:11, 1599-1608

  135. 135

    Micronutrients in Cancer Prevention. In: Micronutrients in Health and Disease. CRC Press, 2010:103-131.

  136. 136

    Cheryl D. Toner, Cindy D. Davis, John A. Milner. (2010) The Vitamin D and Cancer Conundrum: Aiming at a Moving Target. Journal of the American Dietetic Association 110:10, 1492-1500

  137. 137

    Harvey G. Moore. (2010) Colorectal Cancer: What Should Patients and Families Be Told to Lower the Risk of Colorectal Cancer?. Surgical Oncology Clinics of North America 19:4, 693-710

  138. 138

    Jean-Claude Souberbielle, Jean-Jacques Body, Joan M. Lappe, Mario Plebani, Yehuda Shoenfeld, Thomas J. Wang, Heike A. Bischoff-Ferrari, Etienne Cavalier, Peter R. Ebeling, Patrice Fardellone, Sara Gandini, Damien Gruson, Alain P. Guérin, Lene Heickendorff, Bruce W. Hollis, Sofia Ish-Shalom, Guillaume Jean, Philipp von Landenberg, Alvaro Largura, Tomas Olsson, Charles Pierrot-Deseilligny, Stefan Pilz, Angela Tincani, Andre Valcour, Armin Zittermann. (2010) Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: Recommendations for clinical practice. Autoimmunity Reviews 9:11, 709-715

  139. 139

    V. Fedirko, R. M. Bostick, M. Goodman, W. D. Flanders, M. D. Gross. (2010) Blood 25-Hydroxyvitamin D3 Concentrations and Incident Sporadic Colorectal Adenoma Risk: A Pooled Case-Control Study. American Journal of Epidemiology 172:5, 489-500

  140. 140

    Petr Protiva. Nutrition and Colon Cancer Prevention. In: Nutritional Management of Digestive Disorders. CRC Press, 2010:353-363.

  141. 141

    A. Datsis, A. Tsoga, V. Langouretos. (2010) The role of functional foods in the prevention of colorectal cancer. Hellenic Journal of Surgery 82:4, 224-232

  142. 142

    Helen Barrett, Aidan McElduff. (2010) Vitamin D and pregnancy: An old problem revisited. Best Practice & Research Clinical Endocrinology & Metabolism 24:4, 527-539

  143. 143

    Barbara K. Dunn, Peter Greenwald. (2010) Cancer Prevention II: Introduction. Seminars in Oncology 37:4, 321-326

  144. 144

    Aruna V. Krishnan, Srilatha Swami, David Feldman. (2010) Vitamin D and breast cancer: Inhibition of estrogen synthesis and signaling. The Journal of Steroid Biochemistry and Molecular Biology 121:1-2, 343-348

  145. 145

    Edward Giovannucci. (2010) Epidemiology of vitamin D and colorectal cancer: Casual or causal link?. The Journal of Steroid Biochemistry and Molecular Biology 121:1-2, 349-354

  146. 146

    Annemieke Verstuyf, Geert Carmeliet, Roger Bouillon, Chantal Mathieu. (2010) Vitamin D: a pleiotropic hormone. Kidney International 78:2, 140-145

  147. 147

    Patsy Brannon, Mary Picciano, Michelle McGuire. Vitamin D. In: Encyclopedia of Dietary Supplements, Second Edition. CRC Press, 2010:832-840.

  148. 148

    Bruce W. Hollis. (2010) Assessment and Interpretation of Circulating 25-Hydroxyvitamin D and 1,25-Dihydroxyvitamin D in the Clinical Environment. Endocrinology and Metabolism Clinics of North America 39:2, 271-286

  149. 149

    Daniel D. Bikle. (2010) Vitamin D: newly discovered actions require reconsideration of physiologic requirements. Trends in Endocrinology & Metabolism 21:6, 375-384

  150. 150

    Michael F. Holick. (2010) Vitamin D: Extraskeletal Health. Endocrinology and Metabolism Clinics of North America 39:2, 381-400

  151. 151

    Todd M. Gibson, Leah M. Ferrucci, Joseph A. Tangrea, Arthur Schatzkin. (2010) Epidemiological and Clinical Studies of Nutrition. Seminars in Oncology 37:3, 282-296

  152. 152

    Barbara K. Dunn, Peter Greenwald. (2010) Cancer Prevention I: Introduction. Seminars in Oncology 37:3, 190-201

  153. 153

    Neil Binkley, Rekha Ramamurthy, Diane Krueger. (2010) Low Vitamin D Status: Definition, Prevalence, Consequences, and Correction. Endocrinology and Metabolism Clinics of North America 39:2, 287-301

  154. 154

    Graham A. Colditz. (2010) Ensuring long-term sustainability of existing cohorts remains the highest priority to inform cancer prevention and control. Cancer Causes & Control 21:5, 649-656

  155. 155

    Graham A. Colditz, Philip R. Taylor. (2010) Prevention Trials: Their Place in How We Understand the Value of Prevention Strategies. Annual Review of Public Health 31:1, 105-120

  156. 156

    Guangming Liu, Xin Hu, Subhas Chakrabarty. (2010) Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU. International Journal of Cancer 126:3, 631-639

  157. 157

    Kavitha K Reddy, Barbara A Gilchrest. (2010) What Is All This Commotion about Vitamin D?. Journal of Investigative Dermatology 130:2, 321-326

  158. 158

    Marie Courbebaisse, Jean-Claude Souberbielle, Eric Thervet. (2010) Potential Nonclassical Effects of Vitamin D in Transplant Recipients. Transplantation 89:2, 131-137

  159. 159

    Donald L. Trump, Kristin K. Deeb, Candace S. Johnson. (2010) Vitamin D: Considerations in the Continued Development as an Agent for Cancer Prevention and Therapy. The Cancer Journal 16:1, 1-9

  160. 160

    Gerald W. Smetana, Jane S. Sillman. (2010) Update in New Medications for Primary Care. Journal of General Internal Medicine 26:4, 427

  161. 161

    Bodo Lehmann, Michael Meurer. (2010) Vitamin D metabolism. Dermatologic Therapy 23:1, 2-12

  162. 162

    Guri Skeie, Anette Hjartåker, Tonje Braaten, Eiliv Lund. (2009) Dietary change among breast and colorectal cancer survivors and cancer-free women in the Norwegian Women and Cancer cohort study. Cancer Causes & Control 20:10, 1955-1966

  163. 163

    David Borradale, Michael Kimlin. (2009) Vitamin D in health and disease: an insight into traditional functions and new roles for the ‘sunshine vitamin’. Nutrition Research Reviews 22:02, 118

  164. 164

    P. Thermann, T. Seufferlein. (2009) Primäre und sekundäre Prävention sporadischer kolorektaler Karzinome. Der Onkologe 15:12, 1193-1205

  165. 165

    Sihe Wang. (2009) Epidemiology of vitamin D in health and disease. Nutrition Research Reviews 22:02, 188

  166. 166

    Marjorie L McCullough, Roberd M Bostick, Carrie R Daniel, W. Dana Flanders, Aasma Shaukat, Jill Davison, Udaya Rangaswamy, Bruce W Hollis. (2009) Vitamin D Status and Impact of Vitamin D 3 and/or Calcium Supplementation in a Randomized Pilot Study in the Southeastern United States. Journal of the American College of Nutrition 28:6, 678-686

  167. 167

    Han van der Rhee, Jan Willem Coebergh, Esther de Vries. (2009) Sunlight, vitamin D and the prevention of cancer: a systematic review of epidemiological studies. European Journal of Cancer Prevention 18:6, 458-475

  168. 168

    Martin A. Weinstock, Arnold M. Moses. (2009) Skin cancer meets vitamin D: The way forward for dermatology and public health. Journal of the American Academy of Dermatology 61:4, 720-724

  169. 169

    Bruce W. Hollis. (2009) Nutrition: US recommendations fail to correct vitamin D deficiency. Nature Reviews Endocrinology 5:10, 534-536

  170. 170

    K Ng, B M Wolpin, J A Meyerhardt, K Wu, A T Chan, B W Hollis, E L Giovannucci, M J Stampfer, W C Willett, C S Fuchs. (2009) Prospective study of predictors of vitamin D status and survival in patients with colorectal cancer. British Journal of Cancer 101:6, 916-923

  171. 171

    Shari S. Bassuk, JoAnn E. Manson. (2009) Does Vitamin D Protect Against Cardiovascular Disease?. Journal of Cardiovascular Translational Research 2:3, 245-250

  172. 172

    C Palacios, KJ Joshipura, WC Willett. (2009) Nutrition and health: guidelines for dental practitioners. Oral Diseases 15:6, 369-381

  173. 173

    James R Marshall. (2009) Nutrition and colon cancer prevention. Current Opinion in Clinical Nutrition and Metabolic Care 12:5, 539-543

  174. 174

    Neil Binkley. (2009) Is Vitamin D the Fountain of Youth?. Endocrine Practice 15:6, 590-596

  175. 175

    Haibo Xu, Mella McCann, Zhiyu Zhang, Gary H. Posner, Victoria Bingham, Mohamed El-Tanani, Frederick C. Campbell. (2009) Vitamin D receptor modulates the neoplastic phenotype through antagonistic growth regulatory signals. Molecular Carcinogenesis 48:8, 758-772

  176. 176

    Patricia A Thompson, Eugene W Gerner. (2009) Current concepts in colorectal cancer prevention. Expert Review of Gastroenterology & Hepatology 3:4, 369-382

  177. 177

    Michael F. Holick. (2009) Multiple myeloma and cancer: Is there a D-lightful connection?. American Journal of Hematology 84:7, 393-394

  178. 178

    William B. Grant, Sharif B. Mohr. (2009) Ecological Studies Of Ultraviolet B, Vitamin D And Cancer Since 2000. Annals of Epidemiology 19:7, 446-454

  179. 179

    Ann M. Bode, Zigang Dong. (2009) Cancer prevention research — then and now. Nature Reviews Cancer 9:7, 508-516

  180. 180

    Thomas E. Rohan, Abdissa Negassa, Rowan T. Chlebowski, Clementina D. Ceria-Ulep, Barbara B. Cochrane, Dorothy S. Lane, Mindy Ginsberg, Sylvia Wassertheil-Smoller, David L. Page. (2009) A randomized controlled trial of calcium plus vitamin D supplementation and risk of benign proliferative breast disease. Breast Cancer Research and Treatment 116:2, 339-350

  181. 181

    Cedric F. Garland, Edward D. Gorham, Sharif B. Mohr, Frank C. Garland. (2009) Vitamin D for Cancer Prevention: Global Perspective. Annals of Epidemiology 19:7, 468-483

  182. 182

    L. YIN, N. GRANDI, E. RAUM, U. HAUG, V. ARNDT, H. BRENNER. (2009) Meta-analysis: longitudinal studies of serum vitamin D and colorectal cancer risk. Alimentary Pharmacology & Therapeutics 30:2, 113-125

  183. 183

    Alexandra V. Yamshchikov, Nirali S. Desai, Henry M. Blumberg, Thomas R. Ziegler, Vin Tangpricha. (2009) Vitamin D for Treatment and Prevention of Infectious Diseases: A Systematic Review of Randomized Controlled Trials. Endocrine Practice 15:5, 438-449

  184. 184

    C. H. S. Ruxton, E. Derbyshire. (2009) Health impacts of vitamin D: are we getting enough?. Nutrition Bulletin 34:2, 185-197

  185. 185

    Edward Giovannucci. (2009) The Epidemiology of Vitamin D and Cancer Risk. Clinical Reviews in Bone and Mineral Metabolism 7:2, 147-158

  186. 186

    Edward D. Gorham, Sharif B. Mohr, Frank C. Garland, Cedric F. Garland. (2009) Vitamin D for Cancer Prevention and Survival. Clinical Reviews in Bone and Mineral Metabolism 7:2, 159-175

  187. 187

    William B. Grant. (2009) The Health Benefits of Solar Irradiance and Vitamin D and the Consequences of Their Deprivation. Clinical Reviews in Bone and Mineral Metabolism 7:2, 134-146

  188. 188

    Donald Maxwell Parkin, Anne-Helene Olsen, Peter Sasieni. (2009) The potential for prevention of colorectal cancer in the UK. European Journal of Cancer Prevention 18:3, 179-190

  189. 189

    A. Olsen, R. Egeberg, A. Tjonneland. (2009) Re: Calcium Plus Vitamin D Supplementation and the Risk of Breast Cancer. JNCI Journal of the National Cancer Institute 101:9, 690-690

  190. 190

    R. T. Chlebowski, J. Wactawski-Wende, C. Kooperberg, G. L. Anderson. (2009) Response: Re: Calcium Plus Vitamin D Supplementation and the Risk of Breast Cancer. JNCI Journal of the National Cancer Institute 101:9, 690-691

  191. 191

    A. Z. LaCroix, J. Kotchen, G. Anderson, R. Brzyski, J. A. Cauley, S. R. Cummings, M. Gass, K. C. Johnson, M. Ko, J. Larson, J. E. Manson, M. L. Stefanick, J. Wactawski-Wende. (2009) Calcium Plus Vitamin D Supplementation and Mortality in Postmenopausal Women: The Women's Health Initiative Calcium-Vitamin D Randomized Controlled Trial. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 64A:5, 559-567

  192. 192

    Francis B Mimouni, Raanan Shamir. (2009) Vitamin D requirements in the first year of life. Current Opinion in Clinical Nutrition and Metabolic Care 12:3, 287-292

  193. 193

    Philippa H. Youl, Monika Janda, Michael Kimlin. (2009) Vitamin D and sun protection: The impact of mixed public health messages in Australia. International Journal of Cancer 124:8, 1963-1970

  194. 194

    Ivanka Stajner. (2009) Comment on interaction of hormone replacement therapy with calcium and vitamin D supplementation on colorectal cancer risk. International Journal of Cancer 124:7, 1736-1736

  195. 195

    Eric L. Ding, Edward L. Giovannucci. (2009) Reply to Comment on: Interaction of hormone replacement therapy with calcium and Vitamin D supplementation on colorectal cancer risk. International Journal of Cancer 124:7, 1737-1738

  196. 196

    Aasma Shaukat, Murtaza Parekh, Joseph Lipscomb, Uri Ladabaum. (2009) Can calcium chemoprevention of adenoma recurrence substitute or serve as an adjunct for colonoscopic surveillance?. International Journal of Technology Assessment in Health Care 25:02, 222

  197. 197

    Isaac Soo, Leah Gramlich. Colorectal Cancer. In: Food and Nutrients in Disease Management. CRC Press, 2009.

  198. 198

    Marwan G. Fakih, Donald L. Trump, Candace S. Johnson, Lili Tian, Josephia Muindi, Annette Y. Sunga. (2009) Chemotherapy is linked to severe vitamin D deficiency in patients with colorectal cancer. International Journal of Colorectal Disease 24:2, 219-224

  199. 199

    Sharif B. Mohr. (2009) A Brief History of Vitamin D and Cancer Prevention. Annals of Epidemiology 19:2, 79-83

  200. 200

    D. Michal Freedman, Preetha Rajaraman, Barbara Fuhrman, Richard Hoffbeck, Bruce H. Alexander. (2009) Sunlight, hormone replacement status and colorectal cancer risk in postmenopausal women. International Journal of Cancern/a-n/a

  201. 201

    Guiyun Zhou, Jill Stoltzfus, Beth Ann Swan. (2009) Optimizing Vitamin D Status to Reduce Colorectal Cancer Risk: An Evidentiary Review. Clinical Journal of Oncology Nursing 13:4, E3-E17

  202. 202

    D. Albanes. (2008) Vitamin Supplements and Cancer Prevention: Where Do Randomized Controlled Trials Stand?. JNCI Journal of the National Cancer Institute 101:1, 2-4

  203. 203

    Bruce W Hollis. (2008) Assessment of vitamin D status and definition of a normal circulating range of 25-hydroxyvitamin D. Current Opinion in Endocrinology, Diabetes and Obesity 15:6, 489-494

  204. 204

    R. T. Chlebowski, K. C. Johnson, C. Kooperberg, M. Pettinger, J. Wactawski-Wende, T. Rohan, J. Rossouw, D. Lane, M. J. O'Sullivan, S. Yasmeen, R. A. Hiatt, J. M. Shikany, M. Vitolins, J. Khandekar, F. A. Hubbell, . (2008) Calcium Plus Vitamin D Supplementation and the Risk of Breast Cancer. JNCI Journal of the National Cancer Institute 100:22, 1581-1591

  205. 205

    C. Speers, P. Brown. (2008) Breast Cancer Prevention Using Calcium and Vitamin D: A Bright Future?. JNCI Journal of the National Cancer Institute 100:22, 1562-1564

  206. 206

    Anne E Wolff, Andrea N Jones, Karen E Hansen. (2008) Vitamin D and musculoskeletal health. Nature Clinical Practice Rheumatology 4:11, 580-588

  207. 207

    Ian C Logan, Miles D Witham. (2008) Vitamin D in older people. Reviews in Clinical Gerontology 18:04, 287

  208. 208

    Evropi Theodoratou, Susan M. Farrington, Albert Tenesa, Geraldine McNeill, Roseanne Cetnarskyj, Rebecca A. Barnetson, Mary E. Porteous, Malcolm G. Dunlop, Harry Campbell. (2008) Modification of the inverse association between dietary vitamin D intake and colorectal cancer risk by a Fok I variant supports a chemoprotective action of Vitamin D intake mediated through VDR binding. International Journal of Cancer 123:9, 2170-2179

  209. 209

    László Herszényi, Fabio Farinati, Pál Miheller, Zsolt Tulassay. (2008) Chemoprevention of colorectal cancer: feasibility in everyday practice?. European Journal of Cancer Prevention 17:6, 502-514

  210. 210

    (2008) Vitamin D for prevention of chronic disease: the need for continued research. Internal Medicine Journal 38:11, 813-815

  211. 211

    R. Przybelski, S. Agrawal, D. Krueger, J. A. Engelke, F. Walbrun, N. Binkley. (2008) Rapid correction of low vitamin D status in nursing home residents. Osteoporosis International 19:11, 1621-1628

  212. 212

    Michèle Garabédian. (2008) Vitamine D : faut-il revoir les besoins et apports recommandés ?. Cahiers de Nutrition et de Diététique 43:5, 229-234

  213. 213

    David A Bushinsky, Justin Silver. (2008) Nutritional vitamin D: the benefits of supplementation. Current Opinion in Internal Medicine 7:5, 490-492

  214. 214

    Michael F Holick. (2008) Vitamin D: a D-Lightful health perspective. Nutrition Reviews 66, S182-S194

  215. 215

    Pentti Tuohimaa. (2008) Vitamin D, aging, and cancer. Nutrition Reviews 66, S147-S152

  216. 216

    María Elena Martínez, James R. Marshall, Edward Giovannucci. (2008) Diet and cancer prevention: the roles of observation and experimentation. Nature Reviews Cancer 8:9, 694-703

  217. 217

    Edward Giovannucci. (2008) What is the optimal vitamin D level for health?. Therapy 5:5, 655-658

  218. 218

    Charles J. Kahi, Douglas K. Rex, Thomas F. Imperiale. (2008) Screening, Surveillance, and Primary Prevention for Colorectal Cancer: A Review of the Recent Literature. Gastroenterology 135:2, 380-399

  219. 219

    Stefan Pilz, Harald Dobnig, Astrid Fahrleitner-Pammer, Günter Polt, Winfried März. (2008) Vitamin D-Mangel: Ein globales Gesundheitsproblem / Vitamin D deficiency: a global health problem. LaboratoriumsMedizin 32:4, 200-208

  220. 220

    Stefan Pilz, Harald Dobnig, Astrid Fahrleitner-Pammer, Günter Polt, Winfried März. (2008) Vitamin D deficiency: a global health problem 1. LaboratoriumsMedizin 32:4, ---

  221. 221

    Naim M Maalouf. (2008) The noncalciotropic actions of vitamin D: recent clinical developments. Current Opinion in Nephrology and Hypertension 17:4, 408-415

  222. 222

    Olivier Ganry, B. Lapôtre-Ledoux, P. Fardellone, A. Dubreuil. (2008) Bone mass density, subsequent risk of colon cancer and survival in postmenopausal women. European Journal of Epidemiology 23:7, 467-473

  223. 223

    David A Bushinsky, Justin Silver. (2008) Nutritional vitamin D: the benefits of supplementation. Current Opinion in Nephrology and Hypertension 17:4, 345-347

  224. 224

    Roger Bouillon, Heike Bischoff-Ferrari, Walter Willett. (2008) Vitamin D and Health: Perspectives From Mice and Man. Journal of Bone and Mineral Research 23:7, 974-979

  225. 225

    Maria Pufulete. (2008) Intake of dairy products and risk of colorectal neoplasia. Nutrition Research Reviews 21:01,

  226. 226

    Kathleen M. Egan, Lisa B. Signorello, Heather M. Munro, Margaret K. Hargreaves, Bruce W. Hollis, William J. Blot. (2008) Vitamin D insufficiency among African-Americans in the southeastern United States: implications for cancer disparities (United States). Cancer Causes & Control 19:5, 527-535

  227. 227

    Eric L. Ding, Saurabh Mehta, Wafaie W. Fawzi, Edward L. Giovannucci. (2008) Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: Reanalysis of Women's Health Initiative randomized trial. International Journal of Cancer 122:8, 1690-1694

  228. 228

    Ross L. Prentice, Garnet L. Anderson. (2008) The Women's Health Initiative: Lessons Learned. Annual Review of Public Health 29:1, 131-150

  229. 229

    Nadir Arber, Bernard Levin. (2008) Chemoprevention of Colorectal Neoplasia: The Potential for Personalized Medicine. Gastroenterology 134:4, 1224-1237

  230. 230

    (2008) Subgroup Analyses in Clinical Trials. New England Journal of Medicine 358:11, 1199-1200
    Free Full Text

  231. 231

    Tatiana M. Oberyszyn. (2008) Non-melanoma skin cancer: Importance of gender, immunosuppressive status and vitamin D. Cancer Letters 261:2, 127-136

  232. 232

    T J Green, C M Skeaff, J E P Rockell, B J Venn, A Lambert, J Todd, G L Khor, S P Loh, S Muslimatun, R Agustina, S J Whiting. (2008) Vitamin D status and its association with parathyroid hormone concentrations in women of child-bearing age living in Jakarta and Kuala Lumpur. European Journal of Clinical Nutrition 62:3, 373-378

  233. 233

    Kamilia Tai, Allan G. Need, Michael Horowitz, Ian M. Chapman. (2008) Vitamin D, glucose, insulin, and insulin sensitivity. Nutrition 24:3, 279-285

  234. 234

    Silvio Garattini, Vittorio Bertele’. (2008) Do we learn the right things from clinical trials?. European Journal of Clinical Pharmacology 64:2, 115-125

  235. 235

    Frank Grünhage, Matthias Jungck, Christoph Lamberti, Christine Berg, Ursula Becker, Hildegard Schulte-Witte, Dominik Plassmann, Nils Rahner, Stefan Aretz, Nicolaus Friedrichs, Reinhard Buettner, Tilman Sauerbruch, Frank Lammert. (2008) Association of familial colorectal cancer with variants in the E-cadherin (CDH1) and cyclin D1 (CCND1) genes. International Journal of Colorectal Disease 23:2, 147-154

  236. 236

    Umar Asad, Nancy Emenaker, John Milner. Colorectal Cancer Prevention. In: Handbook of Prebiotics. CRC Press, 2008:285-294.

  237. 237

    Michael Asher MA Weingarten, Anca Zalmanovici Trestioreanu, John Yaphe, Michael Asher MA Weingarten. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. In: Cochrane Database of Systematic Reviews. John Wiley & Sons, Ltd, 2008.

  238. 238

    Goran Bjelakovic, Dimitrinka Nikolova, Lise Lotte Gluud, Rosa G Simonetti, Christian Gluud, Goran Bjelakovic. . 2008.

  239. 239

    Jason A. Zell, Frank L. Meyskens. Cancer Prevention, Screening, and Early Detection. In: Abeloff's Clinical Oncology. Elsevier, 2008:361-395.

  240. 240

    F. Berrino, A. Villarini. Fruit and vegetables and cancer. In: Improving the health-promoting properties of fruit and vegetable products. Woodhead Publishing Limited, 2008:75-94.

  241. 241

    Carolyn Compton, Ernie Hawk, Louise Grochow, Fred Lee, Mark Ritter, John E. Niederhuber. Colon Cancer. In: Abeloff's Clinical Oncology. Elsevier, 2008:1477-1534.

  242. 242

    Yu-Jin Paek. (2008) Evidence-based Complementary and Alternative Medicine for Cancer Prevention. Journal of the Korean Medical Association 51:5, 411

  243. 243

    Marci Goldstein Adams, Stacie Geller, Laura Studee. Menopause and Midlife. In: Optimizing Women's Health through Nutrition. CRC Press, 2007.

  244. 244

    Ross L. Prentice. (2007) Observational studies, clinical trials, and the women’s health initiative. Lifetime Data Analysis 13:4, 449-462

  245. 245

    Edward Giovannucci. (2007) Epidemiological Evidence for Vitamin D and Colorectal Cancer. Journal of Bone and Mineral Research 22:S2, V81-V85

  246. 246

    Wang , Rui , Lagakos , Stephen W. , Ware , James H. , Hunter , David J. , Drazen , Jeffrey M. , . (2007) Statistics in Medicine — Reporting of Subgroup Analyses in Clinical Trials. New England Journal of Medicine 357:21, 2189-2194
    Free Full Text

  247. 247

    D. M. Freedman, A. C. Looker, S.-C. Chang, B. I. Graubard. (2007) Prospective Study of Serum Vitamin D and Cancer Mortality in the United States. JNCI Journal of the National Cancer Institute 99:21, 1594-1602

  248. 248

    Sylvain Grenier. (2007) Vitamin D: Two indications for the price of one?. Canadian Pharmacists Journal 140:6, 390-394

  249. 249

    David Z. J. Chu, Glen Gibson, Donald David, Yun Yen. (2007) The Surgeon’s Role in Cancer Prevention. The Model in Colorectal Carcinoma. Annals of Surgical Oncology 14:11, 3054-3069

  250. 250

    William B Grant. (2007) Roles of solar UV radiation and vitamin D in human health and how to obtain vitamin D. Expert Review of Dermatology 2:5, 563-577

  251. 251

    Song-Yi Park, Suzanne P. Murphy, Lynne R. Wilkens, Brian E. Henderson, Laurence N. Kolonel. (2007) Fat and meat intake and prostate cancer risk: The multiethnic cohort study. International Journal of Cancer 121:6, 1339-1345

  252. 252

    Elizabeth T. Jacobs, Patricia A. Thompson, Mar??a Elena Mart??nez. (2007) Diet, Gender, and Colorectal Neoplasia. Journal of Clinical Gastroenterology 41:8, 731-746

  253. 253

    Heide S. Cross. (2007) Extrarenal Vitamin D Hydroxylase Expression and Activity in Normal and Malignant Cells: Modification of Expression by Epigenetic Mechanisms and Dietary Substances. Nutrition Reviews 65, S108-S112

  254. 254

    T Otani, M Iwasaki, S Sasazuki, M Inoue, S Tsugane. (2007) Plasma vitamin D and risk of colorectal cancer: the Japan Public Health Center-Based Prospective Study. British Journal of Cancer 97:3, 446-451

  255. 255

    S. Ding, M. F. McEntee, J. Whelan, M. Zemel. (2007) Adiposity-Related Protection of Intestinal Tumorigenesis: Interaction With Dietary Calcium. Nutrition and Cancer 58:2, 153-161

  256. 256

    K. Wu, D. Feskanich, C. S. Fuchs, W. C. Willett, B. W. Hollis, E. L. Giovannucci. (2007) A Nested Case Control Study of Plasma 25-Hydroxyvitamin D Concentrations and Risk of Colorectal Cancer. JNCI Journal of the National Cancer Institute 99:14, 1120-1129

  257. 257

    Daniel D Bikle. (2007) What is new in vitamin D: 2006???2007. Current Opinion in Rheumatology 19:4, 383-388

  258. 258

    I. T. JOHNSON, E. K. LUND. (2007) Review article: nutrition, obesity and colorectal cancer. Alimentary Pharmacology & Therapeutics 26:2, 161-181

  259. 259

    Ingrid Mühlhauser. (2007) Ist Vorbeugen besser als Heilen?. Zeitschrift für ärztliche Fortbildung und Qualität im Gesundheitswesen - German Journal for Quality in Health Care 101:5, 293.e1-293.e9

  260. 260

    Panagiota N. Mitrou, Demetrius Albanes, Stephanie J. Weinstein, Pirjo Pietinen, Philip R. Taylor, Jarmo Virtamo, Michael F. Leitzmann. (2007) A prospective study of dietary calcium, dairy products and prostate cancer risk (Finland). International Journal of Cancer 120:11, 2466-2473

  261. 261

    Gary G Schwartz, Halcyon G Skinner. (2007) Vitamin D status and cancer: new insights. Current Opinion in Internal Medicine 6:2, 125-130

  262. 262

    Cedric F. Garland, Edward D. Gorham, Sharif B. Mohr, William B. Grant, Edward L. Giovannucci, Martin Lipkin, Harold Newmark, Michael F. Holick, Frank C. Garland. (2007) Vitamin D and prevention of breast cancer: Pooled analysis. The Journal of Steroid Biochemistry and Molecular Biology 103:3-5, 708-711

  263. 263

    Elizabeth T. Jacobs, David S. Alberts, Jose Benuzillo, Bruce W. Hollis, Patricia A. Thompson, María Elena Martínez. (2007) Serum 25(OH)D levels, dietary intake of vitamin D, and colorectal adenoma recurrence. The Journal of Steroid Biochemistry and Molecular Biology 103:3-5, 752-756

  264. 264

    S WEISMAN, D SCHWARTZ. (2007) Studying women in clinical trials: Scientific and legal implications. Gender Medicine 4:1, 3-7

  265. 265

    Barbara A. Gilchrest. (2007) Sun protection and Vitamin D: Three dimensions of obfuscation. The Journal of Steroid Biochemistry and Molecular Biology 103:3-5, 655-663

  266. 266

    Robert P. Heaney. (2007) The case for improving vitamin D status. The Journal of Steroid Biochemistry and Molecular Biology 103:3-5, 635-641

  267. 267

    Edward D. Gorham, Cedric F. Garland, Frank C. Garland, William B. Grant, Sharif B. Mohr, Martin Lipkin, Harold L. Newmark, Edward Giovannucci, Melissa Wei, Michael F. Holick. (2007) Optimal Vitamin D Status for Colorectal Cancer Prevention. American Journal of Preventive Medicine 32:3, 210-216

  268. 268

    Asad Umar, Ellen Richmond, Donna J. Griebel. (2007) Colorectal cancer prevention: Diet, drugs, or nothing. Current Colorectal Cancer Reports 3:1, 16-23

  269. 269

    M. E. Martinez, E. T. Jacobs. (2007) Calcium Supplementation and Prevention of Colorectal Neoplasia: Lessons From Clinical Trials. JNCI Journal of the National Cancer Institute 99:2, 99-100

  270. 270

    J.S. Barkin. (2007) Calcium plus Vitamin D Supplementation and the Risk of Colorectal Cancer. Yearbook of Medicine 2007, 422-424

  271. 271

    Margery L.S. Gass. The women's health initiative—data and discussion. In: Treatment of the Postmenopausal Woman. Elsevier, 2007:611-618.

  272. 272

    M. Norval, A. P. Cullen, F. R. de Gruijl, J. Longstreth, Y. Takizawa, R. M. Lucas, F. P. Noonan, J. C. van der Leun. (2007) The effects on human health from stratospheric ozone depletion and its interactions with climate change. Photochemical & Photobiological Sciences 6:3, 232

  273. 273

    Elizabeth Tran, Barbara Demmig-Adams. (2007) Vitamins and minerals: powerful medicine or potent toxins?. Nutrition & Food Science 37:1, 50-60

  274. 274

    Hiroyasu Yamamoto. (2007) Nihon Toseki Igakkai Zasshi 40:1, 40-42

  275. 275

    Debasish Das, Nadir Arber, Janusz A. Jankowski. (2007) Chemoprevention of Colorectal Cancer. Digestion 76:1, 51-67

  276. 276

    P.J. Loehrer. (2007) Calcium plus Vitamin D Supplementation and the Risk of Colorectal Cancer. Yearbook of Oncology 2007, 14-16

  277. 277

    Ross L. Prentice. 1 Statistical Methods and Challenges in Epidemiology and Biomedical Research. Elsevier, 2007:1-27.

  278. 278

    Aesun Shin, Honglan Li, Xiao-Ou Shu, Gong Yang, Yu-Tang Gao, Wei Zheng. (2006) Dietary intake of calcium, fiber and other micronutrients in relation to colorectal cancer risk: Results from the Shanghai Women's Health Study. International Journal of Cancer 119:12, 2938-2942

  279. 279

    Dairy Foods and Cancer. In: Handbook of Dairy Foods and Nutrition, Third Edition. CRC Press, 2006:141-179.

  280. 280

    Levine , Joel S. , Ahnen , Dennis J. , . (2006) Adenomatous Polyps of the Colon. New England Journal of Medicine 355:24, 2551-2557
    Full Text

  281. 281

    Roger Bouillon, Guy Eelen, Lieve Verlinden, Chantal Mathieu, Geert Carmeliet, Annemieke Verstuyf. (2006) Vitamin D and cancer. The Journal of Steroid Biochemistry and Molecular Biology 102:1-5, 156-162

  282. 282

    Edward Giovannucci, Esther K. Wei. (2006) Influence of micronutrients and related genes on colorectal cancer risk. Current Colorectal Cancer Reports 2:4, 211-216

  283. 283

    Jacqueline L. Wolf. (2006) Uniquely Women's Issues in Colorectal Cancer Screening. The American Journal of Gastroenterology 101:s3, S625-S629

  284. 284

    Tim Green, C. Murray Skeaff. (2006) Does the vitamin D status of Australians and New Zealanders need improving and how do we do it?. Nutrition & Dietetics 63:4, 196-198

  285. 285

    Suzanne Oparil. (2006) Women and Hypertension. Cardiology in Review 14:6, 267-275

  286. 286

    (2006) Scientific surgery. British Journal of Surgery 93:11, 1437-1437

  287. 287

    &NA;. (2006) The role of calcium in peri- and postmenopausal women. Menopause 13:6, 862-877

  288. 288

    Srinivasan Vijayakumar, Philip S. Boerner, Rajeshwari R. Mehta, S. Packianathan, Rajendra G. Mehta, Tapas K. Das Gupta. (2006) Clinical Trials Using Chemopreventive Vitamin D Analogs in Breast Cancer. The Cancer Journal 12:6, 445-450

  289. 289

    Harold L. Newmark, Robert P. Heaney. (2006) Calcium, Vitamin D, and Risk Reduction of Colorectal Cancer. Nutrition and Cancer 56:1, 1-2

  290. 290

    Erick P. Chan, Gary R. Lichtenstein. (2006) Chemoprevention: Risk Reduction with Medical Therapy of Inflammatory Bowel Disease. Gastroenterology Clinics of North America 35:3, 675-712

  291. 291

    Bertagnolli , Monica M. , Eagle , Craig J. , Zauber , Ann G. , Redston , Mark , Solomon , Scott D. , Kim , KyungMann , Tang , Jie , Rosenstein , Rebecca B. , Wittes , Janet , Corle , Donald , Hess , Timothy M. , Woloj , G. Mabel , Boisserie , Frédéric Anderson , William F. , Viner , Jaye L. , Bagheri , Donya , Burn , John , Chung , Daniel C. , Dewar , Thomas , Foley , T. Raymond , Hoffman , Neville , Macrae , Finlay , Pruitt , Ronald E. , Saltzman , John R. , Salzberg , Bruce , Sylwestrowicz , Thomas , Gordon , Gary B. , Hawk , Ernest T. , . (2006) Celecoxib for the Prevention of Sporadic Colorectal Adenomas. New England Journal of Medicine 355:9, 873-884
    Free Full Text

  292. 292

    A. Vermes. (2006) Calcium plus vitamine-D-suppletie en het risico op colonkanker. Medisch-Farmaceutische Mededelingen 44:7, 199-200

  293. 293

    Gérard Lledo, Pascal Artru. (2006) Calcium et cancer colorectal chez la femme ménopausée: échec et mat!. Acta Endoscopica 36:3, 369-370

  294. 294

    (2006) Calcium plus Vitamin D and the Risk of Colorectal Cancer. New England Journal of Medicine 354:21, 2287-2288
    Free Full Text

  295. 295

    Katy Cherry. (2006) Dietary interventions and colorectal cancer risk. Nature Clinical Practice Gastroenterology & Hepatology 3:5, 244-245

  296. 296

    Rebecca Ireland. (2006) Calcium plus vitamin D3 supplementation does not reduce risk of colorectal cancer. Nature Clinical Practice Oncology 3:5, 231-231

  297. 297

    G. G. Schwartz, W. J. Blot. (2006) Vitamin D Status and Cancer Incidence and Mortality: Something New Under the Sun. JNCI Journal of the National Cancer Institute 98:7, 428-430

  298. 298

    E. Giovannucci, Y. Liu, E. B. Rimm, B. W. Hollis, C. S. Fuchs, M. J. Stampfer, W. C. Willett. (2006) Prospective Study of Predictors of Vitamin D Status and Cancer Incidence and Mortality in Men. JNCI Journal of the National Cancer Institute 98:7, 451-459

  299. 299

    Chang-Hsing Lee, Jian-Jung Chen, Wen-Miin Liang, Billie M. Spaight. (2006) Attitudes and Intentions of Patients Toward Integrated Chinese and Western Medicine in Taiwan; Questions About Questions. The Journal of Alternative and Complementary Medicine 12:3, 233-236

  300. 300

    Philip E Lee, Janet E McElhaney, Larry Dian. (2006) Calcium and vitamin D supplementation for the prevention of fractures in postmenopausal women. Aging Health 2:2, 241-243

  301. 301

    Jackson , Rebecca D. , LaCroix , Andrea Z. , Gass , Margery , Wallace , Robert B. , Robbins , John , Lewis , Cora E. , Bassford , Tamsen , Beresford , Shirley A.A. , Black , Henry R. , Blanchette , Patricia , Bonds , Denise E. , Brunner , Robert L. , Brzyski , Robert G. , Caan , Bette , Cauley , Jane A. , Chlebowski , Rowan T. , Cummings , Steven R. , Granek , Iris , Hays , Jennifer , Heiss , Gerardo , Hendrix , Susan L. , Howard , Barbara V. , Hsia , Judith , Hubbell , F. Allan , Johnson , Karen C. , Judd , Howard , Kotchen , Jane Morley , Kuller , Lewis H. , Langer , Robert D. , Lasser , Norman L. , Limacher , Marian C. , Ludlam , Shari , Manson , JoAnn E. , Margolis , Karen L. , McGowan , Joan , Ockene , Judith K. , O'Sullivan , Mary Jo , Phillips , Lawrence , Prentice , Ross L. , Sarto , Gloria E. , Stefanick , Marcia L. , Van Horn , Linda , Wactawski-Wende , Jean , Whitlock , Evelyn , Anderson , Garnet L. , Assaf , Annlouise R. , Barad , David , . (2006) Calcium plus Vitamin D Supplementation and the Risk of Fractures. New England Journal of Medicine 354:7, 669-683
    Free Full Text

  302. 302

    Forman , Michele R. , Levin , Bernard , . (2006) Calcium plus Vitamin D3 Supplementation and Colorectal Cancer in Women. New England Journal of Medicine 354:7, 752-754
    Full Text

  303. 303

    Reynold Spector, Elliot S. Vesell. (2006) The Heart of Drug Discovery and Development: Rational Target Selection. Pharmacology 77:2, 85-92

Letters

Trends

Most Viewed (Last Week)